<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1247" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1247/" /><meta name="ncbi_pagename" content="BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/12/15" /><meta name="citation_author" content="Nancie Petrucelli" /><meta name="citation_author" content="Mary B Daly" /><meta name="citation_author" content="Tuya Pal" /><meta name="citation_pmid" content="20301425" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1247/" /><meta name="citation_keywords" content="HBOC" /><meta name="citation_keywords" content="HBOC" /><meta name="citation_keywords" content="BRCA1 Hereditary Breast and Ovarian Cancer" /><meta name="citation_keywords" content="BRCA2 Hereditary Breast and Ovarian Cancer" /><meta name="citation_keywords" content="Breast cancer type 1 susceptibility protein" /><meta name="citation_keywords" content="Breast cancer type 2 susceptibility protein" /><meta name="citation_keywords" content="BRCA1" /><meta name="citation_keywords" content="BRCA2" /><meta name="citation_keywords" content="BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Nancie Petrucelli" /><meta name="DC.Contributor" content="Mary B Daly" /><meta name="DC.Contributor" content="Tuya Pal" /><meta name="DC.Date" content="2016/12/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1247/" /><meta name="description" content="BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (includes fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The exact cancer risks differ slightly depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant." /><meta name="og:title" content="BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer" /><meta name="og:type" content="book" /><meta name="og:description" content="BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (includes fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The exact cancer risks differ slightly depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1247/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/brca1/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1247/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C7C39DFC874F10000000005760283.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1247_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1247_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bcl11a-id/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/spg17/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1247_"><span class="title" itemprop="name"><i>BRCA1-</i> and <i>BRCA2</i>-Associated Hereditary Breast and Ovarian Cancer</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: HBOC</div><p class="contrib-group"><span itemprop="author">Nancie Petrucelli</span>, MS, <span itemprop="author">Mary B Daly</span>, MD, PhD, and <span itemprop="author">Tuya Pal</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1247_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1247_ai__"><div class="contrib half_rhythm"><span itemprop="author">Nancie Petrucelli</span>, MS<div class="affiliation small">Wayne State University School of Medicine/Detroit Medical Center <br />Karmanos Cancer Institute, Cancer Genetic Counseling Service <br />Detroit, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.sonamrak@lecurtep" class="oemail">gro.sonamrak@lecurtep</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mary B Daly</span>, MD, PhD<div class="affiliation small">Chair, Department of Clinical Genetics<br />Fox Chase Cancer Center <br />Philadelphia, Pennsylvania<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cccf@ylad_bm" class="oemail">ude.cccf@ylad_bm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Tuya Pal</span>, MD<div class="affiliation small">Moffitt Cancer Center<br />Tampa, Florida<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.ttiffom@lap.ayut" class="oemail">gro.ttiffom@lap.ayut</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 4, 1998</span>; Last Update: <span itemprop="dateModified">December 15, 2016</span>.</p><p><em>Estimated reading time: 47 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="brca1.Summary" itemprop="description"><h2 id="_brca1_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>BRCA1-</i> and <i>BRCA2-</i>associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (includes fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The exact cancer risks differ slightly depending on whether HBOC is caused by a <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant<i>.</i></p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>BRCA1</i> and <i>BRCA2</i> HBOC is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRCA1</i> or <i>BRCA2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> National Comprehensive Cancer Network guidelines suggest that women with a <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> could consider bilateral mastectomy as a primary surgical treatment of breast cancer because of their elevated rate of ipsilateral and contralateral breast cancer. Treatment of ovarian and other cancers in individuals with a <i>BRCA1</i>/<i>2</i> pathogenic variant is similar to that for <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> cancers.</p><p><i>Prevention of primary manifestations:</i> Prophylactic bilateral mastectomy, prophylactic oophorectomy, and chemoprevention (e.g., tamoxifen) have been used for breast cancer prevention, but have not been assessed by randomized trials in high-risk women. Prophylactic oophorectomy for ovarian cancer prevention.</p><p><i>Surveillance:</i> Breast cancer screening in women relies on a combination of monthly breast self-examination, annual or semiannual clinical breast examination, annual mammography, and breast MRI. Annual transvaginal ultrasound and CA-125 concentration beginning at age 35 years may be considered for ovarian cancer screening. However, this screening has not been effective in detecting early-stage ovarian cancer, either in high-risk or average-risk women. For men, breast cancer screening includes breast self-examination education and training and annual clinical breast examination beginning at age 35. Annual prostate cancer screening should begin at age 45. Screening for melanoma should be individualized based on the family history. Screening of asymptomatic individuals for pancreatic cancer is not generally recommended.</p><p><i>Evaluation of relatives at risk:</i> Once a cancer-predisposing <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in a family, testing of at-risk relatives can identify those family members who also have the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pathogenic variant and thus need increased surveillance and early intervention when a cancer is identified.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Germline pathogenic variants in <i>BRCA1</i> and <i>BRCA2</i> are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The vast majority of individuals with a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have inherited it from a parent. However, because of incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, variable age of cancer development, cancer risk reduction resulting from prophylactic surgery, or early death, not all individuals with a <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant have a parent <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with cancer.</p><p>Offspring of an individual with a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of inheriting the variant. Prenatal testing is possible for pregnancies at increased risk if the cancer-predisposing variant in the family is known; however, requests for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of adult-onset diseases are uncommon and require careful <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p></div></div><div id="brca1.Diagnosis"><h2 id="_brca1_Diagnosis_">Diagnosis</h2><div id="brca1.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>BRCA1-</i> and <i>BRCA2</i>-associated hereditary breast and ovarian cancer (HBOC) <b>should be suspected</b> in individuals with a personal or family history (1<sup>st</sup>-, 2<sup>nd</sup>-, or 3<sup>rd</sup>-degree relative in either lineage) of any of the following characteristics [<a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian</a>]:</p><ul><li class="half_rhythm"><div>Breast cancer diagnosed at or before age 50 years</div></li><li class="half_rhythm"><div>Ovarian cancer</div></li><li class="half_rhythm"><div>Multiple primary breast cancers either in one or both breasts</div></li><li class="half_rhythm"><div>Male breast cancer</div></li><li class="half_rhythm"><div>Triple-negative (estrogen receptor-negative, progesterone receptor-negative, and HER2/neu [human epidermal growth factor receptor 2]-negative) breast cancer, particularly when diagnosed before age 60 years</div></li><li class="half_rhythm"><div>The combination of pancreatic cancer and/or prostate cancer (Gleason score &#x02265;7) with breast cancer, and/or ovarian cancer</div></li><li class="half_rhythm"><div>Breast cancer diagnosed at any age in an individual of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> ancestry</div></li><li class="half_rhythm"><div>Two or more relatives with breast cancer, one under age 50</div></li><li class="half_rhythm"><div>Three or more relatives with breast cancer at any age</div></li><li class="half_rhythm"><div>A previously identified <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family</div></li></ul><p>Notes: (1) "Breast cancer" includes both invasive cancer and ductal carcinoma in situ (DCIS). (2) "Ovarian cancer" includes epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.</p><div id="brca1.Probability_Models_for_BRCA12_Path"><h4>Probability Models for <i>BRCA1/2</i> Pathogenic Variants</h4><p>Several models have been developed to estimate the likelihood that an individual or family has a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRCA1</i> or <i>BRCA2</i> [<a class="bk_pop" href="#brca1.REF.parmigiani.1998.145">Parmigiani et al 1998</a>, <a class="bk_pop" href="#brca1.REF.frank.2002.1480">Frank et al 2002</a>, <a class="bk_pop" href="#brca1.REF.antoniou.2004.1580">Antoniou et al 2004</a>, <a class="bk_pop" href="#brca1.REF.evans.2004.474">Evans et al 2004</a>, <a class="bk_pop" href="#brca1.REF.tyrer.2004.1111">Tyrer et al 2004</a>]. According to the American Society of Clinical Oncology (ASCO) policy statement on genetic testing for cancer susceptibility [<a class="bk_pop" href="#brca1.REF.american_society_of_clinical_oncology.2003.2397">American Society of Clinical Oncology 2003</a>], there is no numeric threshold generated from these models that should be used in determining the appropriateness of genetic testing. The use of probability models, however, has been shown to help further discriminate which individuals are more likely to have a <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant, even among experienced providers [<a class="bk_pop" href="#brca1.REF.euhus.2002.844">Euhus et al 2002</a>, <a class="bk_pop" href="#brca1.REF.de_la_hoya.2003.503">de la Hoya et al 2003</a>]. For more information about probability models for <i>BRCA1</i>/<i>2</i> pathogenic variants, click <a href="/books/NBK1247/bin/brca1-probability_models.pdf">here</a>.</p></div></div><div id="brca1.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>BRCA1</i>- and <i>BRCA2</i>-associated hereditary breast and ovarian cancer (HBOC) <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRCA1</i> or <i>BRCA2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figbrca1Tmoleculargenetictestingusedi" rid-ob="figobbrca1Tmoleculargenetictestingusedi">Table 1</a>).</p><p>Note: (1) Molecular testing is most likely to be informative in an individual with a <i>BRCA1</i>/<i>2</i>-associated cancer (e.g., breast cancer at age &#x0003c;50 years, ovarian cancer) and is often referred to as the "best test candidate." Thus, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> ideally should be performed initially on the "best test candidate" as opposed to a family member who may have an unrelated cancer or who may not have a personal history of cancer. (2) If the "best test candidate" is not available, molecular testing may be performed on another individual, without a cancer history, with the understanding that failure to detect a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> does not eliminate the possibility of a <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant being present in the family.</p><p>Molecular testing approaches can include a <b><i>BRCA1</i> and <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> panel</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b><i>BRCA1</i> and <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> panel<i>.</i></b> Sequence analysis of <i>BRCA1</i> and <i>BRCA2</i> is performed concurrently with <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</div><div class="half_rhythm">Targeted analysis can be considered in individuals of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> ancestry by starting with targeted testing for three <i>BRCA1</i> and <i>BRCA2</i> pathogenic founder variants: <i>BRCA1</i> c.68_69delAG (BIC: 185delAG) <i>BRCA1</i> c.5266dupC (BIC: 5382insC), and <i>BRCA2</i> c.5946delT (BIC: 6174delT), which together account for up to 99% of pathogenic variants identified in individuals of Ashkenazi Jewish ancestry. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified by targeted analysis, it may be appropriate to proceed with sequence and <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analyses of <i>BRCA1</i> and <i>BRCA2</i> or a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>.</div><div class="half_rhythm">Note: In a family known to have a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, at-risk adults may be tested for the family-specific germline pathogenic variant. In most cases, relatives at risk need only be tested for the family-specific germline pathogenic variant, except in the following situations:</div><ul><li class="half_rhythm"><div>Individuals of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> heritage should consider testing for all three founder <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants because of the high population frequency of these founder pathogenic variants as well as reports of the coexistence of more than one founder germline <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in some families.</div></li><li class="half_rhythm"><div>Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>BRCA1 or BRACA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on one side of the family and characteristics of HBOC on the other side of the family may consider <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>BRCA1</i> and <i>BRCA2</i>, which would (1) detect the familial <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant if present and also (2) address whether a germline pathogenic variant is present on the other side of the family.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">A <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>BRCA1</i> and <i>BRCA2</i> and other genes of interest (see <a href="#brca1.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="brca1.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>BRCA1</i> and <i>BRCA2</i> Associated Hereditary Breast/Ovarian Cancer (HBOC)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of <i>BRCA1/BRCA2</i> Associated HBOC Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method</th></tr><tr><th headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3" id="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3" id="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA1</i></td><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">66%</td><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;80%&#x000a0;<sup>5</sup></td><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA2</i></td><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">34%</td><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;80%&#x000a0;<sup>5</sup></td><td headers="hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_brca1.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="brca1.TF.1.1"><p class="no_margin">See <a href="/books/NBK1247/#brca1.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="brca1.TF.1.2"><p class="no_margin">See <a href="#brca1.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="brca1.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="brca1.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="brca1.TF.1.5"><p class="no_margin">The majority of pathogenic variants (&#x02265;80%) in <i>BRCA1</i> and <i>BRCA2</i> are detected through whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sequencing, with an additional 10% detected through <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, which may vary across different populations [<a class="bk_pop" href="#brca1.REF.palma.2008.7006">Palma et al 2008</a>, <a class="bk_pop" href="#brca1.REF.ewald.2009.437">Ewald et al 2009</a>, <a class="bk_pop" href="#brca1.REF.kang.2010.579">Kang et al 2010</a>, <a class="bk_pop" href="#brca1.REF.judkins.2012.5210">Judkins et al 2012</a>].</p></div></dd></dl></div></div></div></div></div><div id="brca1.Clinical_Characteristics"><h2 id="_brca1_Clinical_Characteristics_">Clinical Characteristics</h2><div id="brca1.Clinical_Description"><h3>Clinical Description</h3><p><i>BRCA1-</i> and <i>BRCA2-</i>associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk for male and female breast cancer, ovarian cancer (includes fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Estimates of malignancy risk vary considerably depending on the context in which they were derived. The following is a summary of the risk for malignancy in an individual with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant.</p><div id="brca1.T.risk_of_malignancy_in_individual" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Risk of Malignancy in Individuals with a Germline <i>BRCA1</i> or <i>BRCA2</i>-Pathogenic Variant.</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.T.risk_of_malignancy_in_individual_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" style="text-align:left;vertical-align:middle;">Cancer Type</th><th id="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" style="text-align:left;vertical-align:middle;">General Population Risk</th><th id="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Risk for Malignancy&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3" id="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA1</i></th><th headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3" id="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA2</i></th></tr></thead><tbody><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Breast</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">46%-87%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38%-84%</td></tr><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Second primary breast</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2% within 5 years</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">21.1% within 10 yrs<br />83% by age 70</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10.8% within 10 yrs<br />62% by age 70</td></tr><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ovarian</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39%-63%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.5%-27%</td></tr><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Male breast</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.1%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.2%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Up to 8.9%</td></tr><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Prostate</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6% through age 69</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8.6% by age 65</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15% by age 65<br />20% lifetime</td></tr><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pancreatic</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.50%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-3%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-7%</td></tr><tr><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Melanoma (cutaneous &#x00026; ocular)</b></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.6%</td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_1_3 hd_h_brca1.T.risk_of_malignancy_in_individual_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated Risk</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="brca1.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#brca1.REF.ford.1994.692">Ford et al [1994]</a>, <a class="bk_pop" href="#brca1.REF.easton.1995.265">Easton et al [1995]</a>, <a class="bk_pop" href="#brca1.REF.ford.1998.676">Ford et al [1998]</a>, <a class="bk_pop" href="#brca1.REF.robson.1998.1642">Robson et al [1998]</a>, <a class="bk_pop" href="#brca1.REF.breast_cancer_linkage_consortium.1999.1310">Breast Cancer Linkage Consortium [1999]</a>, <a class="bk_pop" href="#brca1.REF.verhoog.2000.119s">Verhoog et al [2000]</a>, <a class="bk_pop" href="#brca1.REF.satagopan.2002.3776">Satagopan et al [2002]</a>, <a class="bk_pop" href="#brca1.REF.thompson.2002.1358">Thompson &#x00026; Easton [2002]</a>, <a class="bk_pop" href="#brca1.REF.hearle.2003.458">Hearle et al [2003]</a>, <a class="bk_pop" href="#brca1.REF.kirova.2005.2304">Kirova et al [2005]</a>, <a class="bk_pop" href="#brca1.REF.robson.2005.44">Robson et al [2005]</a>, <a class="bk_pop" href="#brca1.REF.van_asperen.2005.711">van Asperen et al [2005]</a>, <a class="bk_pop" href="#brca1.REF.chen.2006.863">Chen et al [2006]</a>, <a class="bk_pop" href="#brca1.REF.risch.2006.1694">Risch et al [2006]</a>, <a class="bk_pop" href="#brca1.REF.tai.2007.1811">Tai et al [2007]</a>, <a class="bk_pop" href="#brca1.REF.graeser.2009.5887">Graeser et al [2009]</a>, <a class="bk_pop" href="#brca1.REF.evans.2010.710">Evans et al [2010]</a>, <a class="bk_pop" href="#brca1.REF.van_der_kolk.2010.643">van der Kolk et al [2010]</a>, <a class="bk_pop" href="#brca1.REF.kotejarai.2011.1230">Kote-Jarai et al [2011]</a>, <a class="bk_pop" href="#brca1.REF.iqbal.2012.2005">Iqbal et al [2012]</a>, <a class="bk_pop" href="#brca1.REF.leongamornlert.2012.1697">Leongamornlert et al [2012]</a>, <a class="bk_pop" href="#brca1.REF.moran.2012.235">Moran et al [2012]</a>, <a class="bk_pop" href="#brca1.REF.mavaddat.2013.812">Mavaddat et al [2013]</a>, <a class="bk_pop" href="#brca1.REF.van_den_broek.2015.e0120189">van den Broek et al [2015]</a></p></div></dd></dl></div></div></div><p><b>Breast cancer.</b> Breast cancer is the most common malignancy in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with a lifetime risk ranging from 46% to 87%.</p><p>The first estimates of breast cancer risk associated with <i>BRCA1</i> pathogenic variants was based on 33 families with evidence of linkage to <i>BRCA1</i> with an estimated cumulative risk of 87% by age 70 years [<a class="bk_pop" href="#brca1.REF.ford.1994.692">Ford et al 1994</a>]. For <i>BRCA2</i>, early cumulative breast cancer risk estimates reached 84% by age 70 years [<a class="bk_pop" href="#brca1.REF.ford.1998.676">Ford et al 1998</a>]. Subsequent studies have revealed lower risk estimates. In a US study that included 676 Ashkenazi families and 1272 families of other ethnicities, <a class="bk_pop" href="#brca1.REF.chen.2006.863">Chen et al [2006]</a> estimated the cumulative breast cancer risk in women with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to age 70 years at 46%. <a class="bk_pop" href="#brca1.REF.satagopan.2001.467">Satagopan et al [2001]</a> studied incident breast cancer cases among <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> women and found the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of breast cancer at age 80 years among <i>BRCA1</i> heterozygotes to be 59% (95% CI = 40%-93%) and among <i>BRCA2</i> heterozygotes to be 38% (95% CI = 20%-68%). More recently, in a cohort of 978 individuals with a <i>BRCA1</i> pathogenic variant and 909 individuals with a <i>BRCA2</i> pathogenic variant from the United Kingdom, <a class="bk_pop" href="#brca1.REF.mavaddat.2013.812">Mavaddat et al [2013]</a> estimated the average cumulative breast cancer risks by age 70 in <i>BRCA1</i> heterozygotes to be 60% and 55% for <i>BRCA2</i> heterozygotes (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object" rid-figpopup="figbrca1Triskofmalignancyinindividual" rid-ob="figobbrca1Triskofmalignancyinindividual">Table 2</a>).</p><p>A total of 16 studies comprising 10,180 individuals were recently analyzed to determine overall survival among those with <i>BRCA1</i>/<i>2</i> pathogenic variants [<a class="bk_pop" href="#brca1.REF.templeton.2016.e0154789">Templeton et al 2016</a>]. The pooled analysis showed no association between the presence of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i>/<i>2</i> pathogenic variants and overall survival (HR 1.06, 95% CI 0.84-1.34, p=0.61). The findings were similar when the influence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants were evaluated on overall survival independently (<i>BRCA1</i>: HR 1.20, 95% CI 0.89-1.61, p=0.24; <i>BRCA2</i>: HR 1.01, 95% CI 0.80-1.27, p = 0.95). There, however, appears to be a strong and statistically significant association between estrogen receptor (ER) expression and overall survival in individuals with germline <i>BRCA1</i> pathogenic variants but not with age or progesterone receptor (PR) expression.</p><p><i>BRCA1</i>-related tumors show an excess of medullary histopathology, are of higher histologic grade, are more likely than <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> tumors to be estrogen receptor-negative and progesterone receptor-negative, and are less likely to demonstrate HER2/neu overexpression; thus, <i>BRCA1</i>-related tumors fall within the category of "triple-negative" breast cancer [<a class="bk_pop" href="#brca1.REF.rakha.2008.2568">Rakha et al 2008</a>, <a class="bk_pop" href="#brca1.REF.lee.2011.4373">Lee et al 2011</a>] and overlap with basal-like breast cancers. Several reports have also suggested a link between <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA2</i> pathogenic variants and triple-negative breast cancer. In studies of persons with triple-negative breast cancer, the incidence of germline <i>BRCA2</i> pathogenic variants ranges from 3% to 17% [<a class="bk_pop" href="#brca1.REF.evans.2011.520">Evans et al 2011</a>, <a class="bk_pop" href="#brca1.REF.meyer.2012.e38361">Meyer et al 2012</a>, <a class="bk_pop" href="#brca1.REF.couch.2015.304">Couch et al 2015</a>]. The evidence that a germline <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is associated with poor survival outcomes for breast cancer has been inconsistent [<a class="bk_pop" href="#brca1.REF.verhoog.2000.119s">Verhoog et al 2000</a>, <a class="bk_pop" href="#brca1.REF.bordeleau.2010.13">Bordeleau et al 2010</a>, <a class="bk_pop" href="#brca1.REF.van_den_broek.2015.e0120189">van den Broek et al 2015</a>, <a class="bk_pop" href="#brca1.REF.zhong.2015.211">Zhong et al 2015</a>].</p><p><b>Contralateral breast cancer (CBC).</b> Several studies have reported higher rates of CBC [<a class="bk_pop" href="#brca1.REF.graeser.2009.5887">Graeser et al 2009</a>, <a class="bk_pop" href="#brca1.REF.malone.2010.2404">Malone et al 2010</a>, <a class="bk_pop" href="#brca1.REF.pierce.2010.389">Pierce et al 2010</a>, <a class="bk_pop" href="#brca1.REF.van_der_kolk.2010.643">van der Kolk et al 2010</a>, <a class="bk_pop" href="#brca1.REF.metcalfe.2011a.1384">Metcalfe et al 2011a</a>, <a class="bk_pop" href="#brca1.REF.vichapat.2012.3478">Vichapat et al 2012</a>, <a class="bk_pop" href="#brca1.REF.van_den_broek.2015.e0120189">van den Broek et al 2015</a>] in women treated conservatively. Predictors of CBC include age at first breast cancer, family history of early-onset breast cancer, and the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> <i>BRCA</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#brca1.REF.graeser.2009.5887">Graeser et al 2009</a>, <a class="bk_pop" href="#brca1.REF.malone.2010.2404">Malone et al 2010</a>, <a class="bk_pop" href="#brca1.REF.metcalfe.2011a.1384">Metcalfe et al 2011a</a>, <a class="bk_pop" href="#brca1.REF.van_den_broek.2015.e0120189">van den Broek et al 2015</a>]. The risk for CBC was decreased among women who had undergone prophylactic oophorectomy [<a class="bk_pop" href="#brca1.REF.metcalfe.2011a.1384">Metcalfe et al 2011a</a>]. In an unselected cohort of individuals with breast cancer, ten-year cumulative contralateral breast cancer risks of 21.1% for those with <i>BRCA1</i> pathogenic variants and 10.8% for those with <i>BRCA2</i> pathogenic variants were found.</p><p>Using a cohort of 978 <i>BRCA1</i> and 909 <i>BRCA2</i> heterozygotes from the United Kingdom, Mavaddat et al estimated the cumulative risk of contralateral breast cancer to be 83% in <i>BRCA1</i> heterozygotes and 62% for <i>BRCA2</i> heterozygotes by age 70 [<a class="bk_pop" href="#brca1.REF.mavaddat.2013.812">Mavaddat et al 2013</a>].</p><p><b>Ipsilateral breast cancer.</b> Two case-control studies reported significantly higher rates of ipsilateral breast cancer in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> compared with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> controls [<a class="bk_pop" href="#brca1.REF.haffty.2002.1471">Haffty et al 2002</a>, <a class="bk_pop" href="#brca1.REF.seynaeve.2004.1150">Seynaeve et al 2004</a>], however, other studies have not found an increased risk for ipsilateral breast cancer in those with germline <i>BRCA1</i>/<i>2</i> pathogenic variants when compared with women who had sporadic breast cancer [<a class="bk_pop" href="#brca1.REF.robson.2004.r8">Robson et al 2004</a>, <a class="bk_pop" href="#brca1.REF.graeser.2009.5887">Graeser et al 2009</a>] and also demonstrated a significant ipsilateral breast cancer risk reduction in individuals receiving radiation therapy compared with those who were not receiving radiation therapy [<a class="bk_pop" href="#brca1.REF.metcalfe.2011b.287">Metcalfe et al 2011b</a>].</p><p><b>Ovarian cancer (including fallopian tube and primary peritoneal cancers).</b>
<i>BRCA</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants confer an excessive risk for ovarian cancer ranging from 16.5% to 63%. The first estimates of ovarian cancer risk associated with <i>BRCA1</i> pathogenic variants were as high as 63% by age 70 [<a class="bk_pop" href="#brca1.REF.easton.1995.265">Easton et al 1995</a>] and for <i>BRCA2</i> pathogenic variants were as high as 27% by age 70 [<a class="bk_pop" href="#brca1.REF.ford.1998.676">Ford et al 1998</a>]. Subsequent studies have revealed lower risk estimates. In the US population study that included 676 Ashkenazi families and 1272 families of other ethnicities, <a class="bk_pop" href="#brca1.REF.chen.2006.863">Chen et al [2006]</a> estimated ovarian cancer risk to age 70 years in individuals with a germline <i>BRCA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> at 39% (95% CI = 0.30%-0.50%). <a class="bk_pop" href="#brca1.REF.satagopan.2002.3776">Satagopan et al [2002]</a> found the estimated <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of ovarian cancer at age 70 years among <i>BRCA1</i> heterozygotes to be 37% (95% CI = 25%-71%) and among <i>BRCA2</i> heterozygotes to be 21% (95% CI = 13%-41%). More recently, in a cohort of 978 <i>BRCA1</i> and 909 <i>BRCA2</i> heterozygotes from the United Kingdom, <a class="bk_pop" href="#brca1.REF.mavaddat.2013.812">Mavaddat et al [2013]</a> estimated the average cumulative risks by age 70 in <i>BRCA1</i> heterozygotes to be 59% for ovarian cancer and 16.5% for <i>BRCA2</i> heterozygotes (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object" rid-figpopup="figbrca1Triskofmalignancyinindividual" rid-ob="figobbrca1Triskofmalignancyinindividual">Table 2</a>).</p><p>An excess of serous adenocarcinomas have been observed in women with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> or <i>BRCA2</i> pathogenic variants [<a class="bk_pop" href="#brca1.REF.mclaughlin.2013.141">McLaughlin et al 2013</a>]. Serous adenocarcinomas are generally of higher grade and exhibit prominent intraepithelial lymphocytes, marked nuclear atypia, and abundant mitoses [<a class="bk_pop" href="#brca1.REF.fujiwara.2012.1170">Fujiwara et al 2012</a>]. Given recent advances in the understanding of the molecular pathways of ovarian cancer, it has been concluded that most cases of high-grade serous cancers arise from the fallopian tubes rather than the ovaries [<a class="bk_pop" href="#brca1.REF.daly.2015.342">Daly et al 2015</a>].</p><p>Studies on ovarian cancer survival in women with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have yielded conflicting results. A pooled analysis of 26 observational studies found a more favorable survival rate among individuals with a detectable <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant compared to individuals without a <i>BRCA1</i>/<i>2</i> pathogenic variant, (<i>BRCA1</i> HR 0.78, 95% CI 0.68-0.89; <i>BRCA2</i> HR 0.61, 95% CI 0.50-0.76). These results persisted when controlling for stage, grade, histology, and age at diagnosis [<a class="bk_pop" href="#brca1.REF.bolton.2012.382">Bolton et al 2012</a>]. A large population-based case-control study found a higher response to platinum-based therapy, longer progression-free survival, and improved overall survival among individuals with a germline <i>BRCA1</i>/<i>2</i> pathogenic variant [<a class="bk_pop" href="#brca1.REF.alsop.2012.2654">Alsop et al 2012</a>]. Similarly, individuals with platinum-sensitive epithelial ovarian tumors were more likely to have germline <i>BRCA1</i>/<i>2</i> pathogenic variants than individuals with platinum-resistant tumors [<a class="bk_pop" href="#brca1.REF.dann.2012.677">Dann et al 2012</a>]. More recently, in a large series of unselected individuals with ovarian cancer, the short-term survival of individuals with ovarian cancer with germline <i>BRCA1</i>/<i>2</i> pathogenic variants was better than that of individuals without an identified BRCA1/2 pathogenic variant, however, the survival advantage was short lived and did not lead to a long-term survival benefit [<a class="bk_pop" href="#brca1.REF.mclaughlin.2013.141">McLaughlin et al 2013</a>].</p><p><b>Male breast cancer.</b> Based on data from 1939 families with 97 male subjects with breast cancer, the risk of developing breast cancer in males with a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were evaluated. The cumulative risk of breast cancer was higher in both <i>BRCA1</i> and <i>BRCA2</i> male heterozygotes than in males without a <i>BRCA1/2</i> pathogenic variant at all ages. With respect to the relative risks of developing breast cancer, the risk was higher for men in their 30s and 40s and decreased with increasing age. When compared to <i>BRCA1</i>, males with <i>BRCA2</i> pathogenic variants had higher relative and cumulative risks. The estimated cumulative risk of breast cancer for males with <i>BRCA1</i> pathogenic variants at age 70 years was 1.2% (95% CI 0.22%-2.8%) and for males with a <i>BRCA2</i> pathogenic variant was 6.8% (95% CI 3.2%-12%) [<a class="bk_pop" href="#brca1.REF.tai.2007.1811">Tai et al 2007</a>].</p><p>In the largest study of families with BRCA2 to date, using both retrospective and prospective analyses of 321 families, three breast cancers occurred in male first-degree relatives, suggesting a risk for male breast cancer to 80 years of 8.9% [<a class="bk_pop" href="#brca1.REF.evans.2010.710">Evans et al 2010</a>] (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object" rid-figpopup="figbrca1Triskofmalignancyinindividual" rid-ob="figobbrca1Triskofmalignancyinindividual">Table 2</a>).</p><p><b>Prostate cancer.</b> A series of 913 males with prostate cancer, ranging in age from 36 to 86 years, were screened for <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> pathogenic variants; four pathogenic variants were identified; three of which were identified in individuals diagnosed at or before age 65 years. Based on previously estimated population frequencies of <i>BRCA1</i> pathogenic variants, it was estimated that <i>BRCA1</i> pathogenic variants confer a relative risk of prostate cancer of approximately 3.7-fold (95% CI 1.02-9.6), which translates to an 8.6% cumulative risk by age 65 years [<a class="bk_pop" href="#brca1.REF.leongamornlert.2012.1697">Leongamornlert et al 2012</a>].</p><p>The lifetime risk for prostate cancer in males with <i>BRCA2</i> pathogenic variants has been estimated at 20% [<a class="bk_pop" href="#brca1.REF.breast_cancer_linkage_consortium.1999.1310">Breast Cancer Linkage Consortium 1999</a>]. In 2011, Kote-Jarai et al screened 1864 males with prostate cancer diagnosed between age 36 and 88 years for <i>BRCA2</i> pathogenic variants. Nineteen protein-truncating variants were identified, all of which occurred in individuals who were diagnosed with prostate cancer at or before age 65 years. Based on previously estimated frequencies of <i>BRCA2</i> pathogenic variants, it was estimated that <i>BRCA2</i> pathogenic variants confer an increased relative risk of prostate cancer of approximately 8.6-fold (95% CI 5.1-12.6) by age 65 years corresponding to an absolute risk of approximately 15% by age 65 years [<a class="bk_pop" href="#brca1.REF.kotejarai.2011.1230">Kote-Jarai et al 2011</a>]. In addition, <i>BRCA2</i>-related prostate cancer has been associated with a higher histologic grade [<a class="bk_pop" href="#brca1.REF.gallagher.2010.2115">Gallagher et al 2010</a>] and results in a poorer overall survival [<a class="bk_pop" href="#brca1.REF.thorne.2011.1002">Thorne et al 2011</a>] (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object" rid-figpopup="figbrca1Triskofmalignancyinindividual" rid-ob="figobbrca1Triskofmalignancyinindividual">Table 2</a>).</p><p><b>Pancreatic cancer.</b> An increased risk for pancreatic (adenocarcinoma) cancer has been associated with pathogenic variants in <i>BRCA1</i> and <i>BRCA2</i>. In the cross-sectional study of the <a class="bk_pop" href="#brca1.REF.breast_cancer_linkage_consortium.1999.1310">Breast Cancer Linkage Consortium [1999]</a>, <a class="bk_pop" href="#brca1.REF.thompson.2002.1358">Thompson &#x00026; Easton [2002]</a> reported a significant increase in the risk for pancreatic cancer in those with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> pathogenic variants (RR=2.26, 95% CI=1.26-4.06, P=0.004) and in those with <i>BRCA2</i> pathogenic variants (RR=3.51, 95% CI=1.87-6.58, P=0.0012). <a class="bk_pop" href="#brca1.REF.risch.2006.1694">Risch et al [2006]</a> estimated the risk of pancreatic cancer among relatives of females with invasive ovarian cancer in 1171 unselected females with ovarian cancer in Ontario. The relative risk for pancreatic cancer was 3.1 (95% CI=0.45-21) in relatives of those with <i>BRCA1</i> pathogenic variants and 6.6% (95% CI=1.9-23) in relatives of those with <i>BRCA2</i> pathogenic variants, compared to relatives of those without pathogenic variants. More recently, a prospective study of 5149 females with <i>BRCA1</i> or <i>BRCA2</i> pathogenic variants showed a statistically significant 2.4-fold increase in the incidence of pancreatic cancer and &#x02013; unlike in previous studies &#x02013; the increase in the incidence of pancreatic cancer was similar for <i>BRCA1</i> (SIR=2.55) and <i>BRCA2</i> (SIR=2.13) [<a class="bk_pop" href="#brca1.REF.iqbal.2012.2005">Iqbal et al 2012</a>] (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object" rid-figpopup="figbrca1Triskofmalignancyinindividual" rid-ob="figobbrca1Triskofmalignancyinindividual">Table 2</a>).</p><p><b>Melanoma.</b> Although it is less well studied, the literature suggests that melanoma risk, both cutaneous and ocular, may be elevated in some but not all families with a <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#brca1.REF.breast_cancer_linkage_consortium.1999.1310">Breast Cancer Linkage Consortium 1999</a>, <a class="bk_pop" href="#brca1.REF.hearle.2003.458">Hearle et al 2003</a>, <a class="bk_pop" href="#brca1.REF.van_asperen.2005.711">van Asperen et al 2005</a>]. An analysis of 490 families with <i>BRCA1</i>/<i>2</i> pathogenic variants showed an increased risk for ocular melanoma in individuals with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA2</i> pathogenic variants (RR=99.4, 95%CI=11.1-359.8) [<a class="bk_pop" href="#brca1.REF.moran.2012.235">Moran et al 2012</a>] (see <a class="figpopup" href="/books/NBK1247/table/brca1.T.risk_of_malignancy_in_individual/?report=objectonly" target="object" rid-figpopup="figbrca1Triskofmalignancyinindividual" rid-ob="figobbrca1Triskofmalignancyinindividual">Table 2</a>).</p><p><b>Other cancers.</b> In addition to the above-mentioned cancers, individuals with <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants may be at a higher risk for additional malignancies based on family-based studies as well as case-control studies [<a class="bk_pop" href="#brca1.REF.breast_cancer_linkage_consortium.1999.1310">Breast Cancer Linkage Consortium 1999</a>, <a class="bk_pop" href="#brca1.REF.thompson.2001.410">Thompson et al 2001</a>, <a class="bk_pop" href="#brca1.REF.van_asperen.2005.711">van Asperen et al 2005</a>], although the absolute risks for these other cancers are small. The Breast Cancer Linkage Consortium reported an increased relative risk for cancers of the uterine body and cervix, with relative risks of 2.6 and 3.7, in women younger than age 65 years with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#brca1.REF.thompson.2002.1358">Thompson &#x00026; Easton 2002</a>]. The Netherlands Collaborative Group on Hereditary Breast Cancer reported statistically increased relative risks for cancers of the gallbladder and bile duct, with relative risks of 3.5 and 5.0, respectively [<a class="bk_pop" href="#brca1.REF.van_asperen.2005.711">van Asperen et al 2005</a>]. It is important to note, however, that in some of these studies, diagnoses were not consistently confirmed by pathology and therefore, excess risk of cervix and uterus as well as gallbladder and bile duct cancers may represent misclassifications of ovarian and pancreatic cancers, respectively. Furthermore, data suggesting a causative link between endometrial cancer and pathogenic variants of <i>BRCA1</i>/<i>2</i> may be related to tamoxifen exposure [<a class="bk_pop" href="#brca1.REF.beiner.2007.7">Beiner et al 2007</a>] rather than the presence of a pathogenic variant, as previous studies have found that uterine papillary serous cancer does not appear to be a manifestation of HBOC [<a class="bk_pop" href="#brca1.REF.goshen.2000.477">Goshen et al 2000</a>]. Finally, initial reports of increased colorectal cancer risk have generally not been replicated [<a class="bk_pop" href="#brca1.REF.gruber.2002.1344">Gruber &#x00026; Petersen 2002</a>, <a class="bk_pop" href="#brca1.REF.niell.2004.15">Niell et al 2004</a>].</p><p>No associated benign tumors or physical abnormalities are presently known to be associated with pathogenic variants in <i>BRCA1</i> or <i>BRCA2</i>.</p></div><div id="brca1.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>Ovarian cancer and primary papillary serous carcinoma of the peritoneum are considerably more common and tend to develop at an earlier age in women with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as compared to women with a germline <i>BRCA2</i> pathogenic variant [<a class="bk_pop" href="#brca1.REF.casey.2005.457">Casey et al 2005</a>, <a class="bk_pop" href="#brca1.REF.yates.2011.463">Yates et al 2011</a>]. However, those with <i>BRCA2</i> pathogenic variants tend to be at greater risk for male breast cancer, prostate cancer, pancreatic cancer, and melanoma.</p></div><div id="brca1.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Some <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been identified in families with <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. Such correlations are not currently used in individual risk assessment and management, but may be in future with appropriate validation.</p><p>Families with protein-truncating <i>BRCA1</i> pathogenic variants from the Breast Cancer Linkage Consortium reported breast cancer risk to be lower with pathogenic variants in the central region of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (nucleotides 2,401-4,190) compared with surrounding regions. Furthermore, ovarian cancer risk was associated with a lower risk with pathogenic variants 3&#x02019; to nucleotide 4,191 [<a class="bk_pop" href="#brca1.REF.thompson.2001.410">Thompson et al 2001</a>].</p><p>Studies in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population have also found higher rates of ovarian cancer in individuals with the c.68_69delAG (BIC: 185delAG) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in the 5' end of <i>BRCA1,</i> as compared to individuals with the c.5266dupC (BIC: 5382insC) pathogenic variant, which is in the 3' end of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#brca1.REF.lubinski.2004.1">Lubinski et al 2004</a>]. However, c.5266dupC pathogenic variants appear to confer a higher risk for breast cancer, including bilateral breast cancer, and both breast and ovarian cancer in the same individual when compared to both c.68_69delAG (BIC: 185delAG) in <i>BRCA1</i> and c.5946delT (BIC: 6174delT) in <i>BRCA2</i> [<a class="bk_pop" href="#brca1.REF.satagopan.2002.3776">Satagopan et al 2002</a>, <a class="bk_pop" href="#brca1.REF.lubinski.2004.1">Lubinski et al 2004</a>].</p><p>An ovarian cancer cluster region (OCCR) in or near <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 in both <i>BRCA1</i> and <i>BRCA2</i> has been identified [<a class="bk_pop" href="#brca1.REF.rebbeck.2015.1347">Rebbeck et al 2015</a>]. Pathogenic variants within the OCCR have been associated with a higher ratio of ovarian to breast cancer than is seen in families with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> elsewhere in the genes.</p><p>In <i>BRCA1</i> and <i>BRCA2</i>, multiple breast cancer cluster regions (BCCR) have been observed and are associated with relatively elevated breast cancer risk and lower ovarian cancer risk [<a class="bk_pop" href="#brca1.REF.rebbeck.2015.1347">Rebbeck et al 2015</a>].</p></div><div id="brca1.Penetrance_Cancer_Risk"><h3>Penetrance (Cancer Risk)</h3><p>Female breast and ovarian cancers remain the most common cancers associated with <i>BRCA1</i>/<i>2</i> pathogenic variants. Females with <i>BRCA1</i>/2 pathogenic variants have up to an 87% risk of developing an associated cancer, while males have up to a 20% risk.</p></div><div id="brca1.Prevalence"><h3>Prevalence</h3><p><i>BRCA1</i>- and <i>BRCA2-</i>associated hereditary breast and ovarian cancer (HBOC) is the most common form of hereditary breast and ovarian cancer and occurs in all ethnic and racial populations. The prevalence of <i>BRCA1</i>/<i>2</i> pathogenic variants in the general population (excluding Ashkenazim) is estimated at 1:400 to 1:500 [<a class="bk_pop" href="#brca1.REF.anglian_breast_cancer_study_group.2000.1301">Anglian Breast Cancer Study Group 2000</a>, <a class="bk_pop" href="#brca1.REF.whittemore.2004b.2078">Whittemore et al 2004b</a>].</p><p><b><a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a>.</b> The combined frequency of the following three pathogenic variants in the Ashkenazi Jewish population is 1:40 [<a class="bk_pop" href="#brca1.REF.king.2003.643">King et al 2003</a>]:</p><ul><li class="half_rhythm"><div><b><i>BRCA1</i> c.68_69delAG</b> (BIC: 185delAG) occurs with a frequency of 1%;</div></li><li class="half_rhythm"><div><b><i>BRCA1</i></b>
<b>c.5266dupC</b> (BIC: 5382insC) has an estimated prevalence of 0.1%-0.15%;</div></li><li class="half_rhythm"><div><b><i>BRCA2</i> c.5946delT</b> (BIC: 6174delT) occurs with a frequency of about 1.52%.</div></li></ul><p>[<a class="bk_pop" href="#brca1.REF.ferla.2007.vi93">Ferla et al 2007</a>]</p></div></div><div id="brca1.Genetically_Related_Allelic_Disord"><h2 id="_brca1_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>Germline pathogenic variants in <i>BRCA2</i> have been associated with the following:</p><ul><li class="half_rhythm"><div>Familial pancreatic cancer [<a class="bk_pop" href="#brca1.REF.ferrone.2009.433">Ferrone et al 2009</a>, <a class="bk_pop" href="#brca1.REF.iqbal.2012.2005">Iqbal et al 2012</a>, <a class="bk_pop" href="#brca1.REF.mocci.2013.803">Mocci et al 2013</a>]</div></li><li class="half_rhythm"><div><a href="/books/n/gene/fa/">Fanconi anemia</a> complementation group FANCD1 [<a class="bk_pop" href="#brca1.REF.howlett.2002.606">Howlett et al 2002</a>, <a class="bk_pop" href="#brca1.REF.stecklein.2012.178">Stecklein &#x00026; Jensen 2012</a>]</div></li></ul></div><div id="brca1.Differential_Diagnosis"><h2 id="_brca1_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Syndromic breast cancer.</b> Individuals with the following cancer susceptibility syndromes and/or genes have an elevated breast cancer risk. In many instances, <i>BRCA1</i> and <i>BRCA2</i> HBOC can be distinguished from these other disorders based on the constellation of tumors present in the family; however, in some cases, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> may be necessary to differentiate.</p><div id="brca1.T.disorders_to_consider_in_the_dif" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of <i>BRCA1-</i> and <i>BRCA2-</i>Associated Hereditary Breast and Ovarian Cancer</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.T.disorders_to_consider_in_the_dif/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.T.disorders_to_consider_in_the_dif_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cancer Susceptibility Syndrome / Gene</th><th id="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lifetime Breast Cancer Risk &#x00026; Other Associated Cancers</th><th id="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other Distinguishing Features</th></tr></thead><tbody><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/li-fraumeni/">Li-Fraumeni syndrome</a></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TP53</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer &#x02264;79%&#x000a0;<sup>1</sup><br />(often pre-menopausal)<br />Soft tissue sarcoma<br />Osteosarcoma<br />Brain tumors<br />Adrenocortical carcinoma<br />Leukemias</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cancers often occur in childhood or young adulthood.<br />Survivors are at increased risk for multiple primary cancers.</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cowden syndrome<br />(see <a href="/books/n/gene/phts/"><i>PTEN</i> Hamartoma Tumor Syndrome</a>)</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PTEN</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer 25%-50%, may be &#x02264;85%&#x000a0;<sup>2</sup><br />Thyroid cancer<br />Renal cell carcinoma<br />Endometrial carcinoma<br />Colorectal cancer</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple hamartomas, macrocephaly, trichilemmomas, papillomatous papules<br />Affected individuals usually present by late 20s</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hgc/">Hereditary diffuse gastric cancer</a></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CDH1</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer 39%-52%&#x000a0;<sup>3</sup><br />(lobular breast cancer)<br />Diffuse gastric cancer</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Majority of cancers occur before age 40 years</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CHEK2</i><br />(OMIM <a href="http://omim.org/entry/604373" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604373</a>)</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CHEK2</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer 25%-39%&#x000a0;<sup>4</sup><br />Prostate cancer&#x000a0;<sup>5</sup><br />Stomach cancer&#x000a0;<sup>5</sup><br />Sarcoma&#x000a0;<sup>5</sup><br />Kidney cancer&#x000a0;<sup>5</sup></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATM</i> heterozygotes<br />(see <a href="/books/n/gene/ataxia-telangiectas/">Ataxia-Telangiectasia</a>)</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATM</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer 17%-52%&#x000a0;<sup>6</sup><br />Other cancers</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PALB2</i><br />(OMIM <a href="http://omim.org/entry/610355" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610355</a>)</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PALB2</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer &#x02264;58%&#x000a0;<sup>7</sup><br />Male breast cancer&#x000a0;<sup>8</sup><br />Pancreatic cancer <sup>9</sup></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pjs/">Peutz-Jeghers syndrome</a></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>STK11</i>&#x000a0;<sup>1</sup></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer 32%-54%<br />Gastrointestinal malignancies<br />Ovarian (mostly SCTAT)<br />Cervical cancer (adenoma malignum)<br />Uterine cancer<br />Pancreatic cancer<br />Sertoli cell testicular cancer<br />Lung cancer</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastrointestinal polyposis, mucocutaneous pigmentation, hyperpigmented macules on the fingers</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bloom/">Bloom's syndrome</a></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BLM</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer risk increased&#x000a0;<sup>10</sup><br />Epithelial carcinoma<br />Lymphoma<br />Leukemia<br />Other cancers</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe pre- &#x00026; postnatal growth deficiency, sparse subcutaneous fat tissue, short stature, sun-sensitive, erythematous skin lesion of the face</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/werner/">Werner syndrome</a></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>WRN</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer risk increased&#x000a0;<sup>11</sup><br />Sarcomas<br />Melanoma<br />Thyroid cancer<br />Hematologic malignancies</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Characterized by the appearance, usually in the 20s, of features associated w/normal aging</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAD51C</i><br />(OMIM <a href="http://omim.org/entry/602774" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">602774</a>)</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAD51C</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ovarian cancer</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer risk unknown</td></tr><tr><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hnpcc/">Lynch syndrome</a></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MLH1</i><br /><i>MSH2</i><br /><i>MSH6</i><br /><i>PMS2</i><br /><i>EPCAM</i></td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ovarian cancer&#x000a0;<sup>12</sup><br />Nonpolyposis colorectal cancer<br />Endometrial cancer<br />Other cancers</td><td headers="hd_h_brca1.T.disorders_to_consider_in_the_dif_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">It is currently unknown whether Lynch syndrome is associated w/increased risk for breast cancer.&#x000a0;<sup>13</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">RR = relative risk</p></div></dd><dt></dt><dd><div><p class="no_margin">MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a></p></div></dd><dt></dt><dd><div><p class="no_margin">SCTAT = sex cord tumor with annular tubules</p></div></dd><dt></dt><dd><div><p class="no_margin">XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="brca1.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#brca1.REF.ruijs.2010.421">Ruijs et al [2010]</a></p></div></dd><dt>2. </dt><dd><div id="brca1.TF.3.2"><p class="no_margin">Lifetime breast cancer risk is estimated at between 25% and 50% among women with Cowden syndrome [<a class="bk_pop" href="#brca1.REF.hobert.2009.687">Hobert &#x00026; Eng 2009</a>]. Other studies have reported risks as high as 85% [<a class="bk_pop" href="#brca1.REF.tan.2012.400">Tan et al 2012</a>, <a class="bk_pop" href="#brca1.REF.bubien.2013.255">Bubien et al 2013</a>, <a class="bk_pop" href="#brca1.REF.ngeow.2014.1818">Ngeow et al 2014</a>, <a class="bk_pop" href="#brca1.REF.nieuwenhuis.2014.57">Nieuwenhuis et al 2014</a>]; however, there are concerns regarding selection bias in these studies.</p></div></dd><dt>3. </dt><dd><div id="brca1.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#brca1.REF.brookswilson.2004.508">Brooks-Wilson et al [2004]</a>, <a class="bk_pop" href="#brca1.REF.kaurah.2007.2360">Kaurah et al [2007]</a></p></div></dd><dt>4. </dt><dd><div id="brca1.TF.3.4"><p class="no_margin"><i>CHEK2</i> variant c.1100delC (<a href="/nuccore/NM_007194.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_007194<wbr style="display:inline-block"></wbr>​.3</a>) associated with estimated two- to threefold increase in breast cancer risk in women and a tenfold increase of risk in men [CHEK2 Breast Cancer Case-Control Consortium 2004, <a class="bk_pop" href="#brca1.REF.bernstein.2006.348">Bernstein et al 2006</a>, <a class="bk_pop" href="#brca1.REF.weischer.2007.57">Weischer et al 2007</a>]</p></div></dd><dt>5. </dt><dd><div id="brca1.TF.3.5"><p class="no_margin">Associated with <i>CHEK2</i> founder alleles: c.1100delC, c.319+1G&#x0003e;A(IVS2+1G&#x0003e;A), p.Ile157Thr (<a href="/nuccore/NM_007194.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_007194<wbr style="display:inline-block"></wbr>​.3</a>) [<a class="bk_pop" href="#brca1.REF.n_slundkoch.2016.1208">N&#x000e4;slund-Koch et al 2016</a>]</p></div></dd><dt>6. </dt><dd><div id="brca1.TF.3.6"><p class="no_margin">The cancer risk to individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <i>ATM</i> disease-causing variants is approximately four times that of the general population, primarily because of an increased risk for breast cancer [<a class="bk_pop" href="#brca1.REF.renwick.2006.873">Renwick et al 2006</a>, <a class="bk_pop" href="#brca1.REF.tavtigian.2009.427">Tavtigian et al 2009</a>, <a class="bk_pop" href="#brca1.REF.goldgar.2011.r73">Goldgar et al 2011</a>, <a class="bk_pop" href="#brca1.REF.roberts.2012.41">Roberts et al 2012</a>]. Some specific pathogenic <i>ATM</i> variants may cause an even higher female breast cancer risk (&#x02264;52%-69%).</p></div></dd><dt>7. </dt><dd><div id="brca1.TF.3.7"><p class="no_margin"><a class="bk_pop" href="#brca1.REF.antoniou.2014.497">Antoniou et al [2014]</a></p></div></dd><dt>8. </dt><dd><div id="brca1.TF.3.8"><p class="no_margin">Male breast cancer has also been observed in families with molecularly confirmed <i>PALB2</i>-associated breast cancer [<a class="bk_pop" href="#brca1.REF.casadei.2011.2222">Casadei et al 2011</a>, <a class="bk_pop" href="#brca1.REF.ding.2011.771">Ding et al 2011</a>].</p></div></dd><dt>9. </dt><dd><div id="brca1.TF.3.9"><p class="no_margin">Germline pathogenic variants in <i>PALB2</i> have been identified in families with multiple cases of pancreatic cancer, but the exact risk for pancreatic cancer conferred by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants in <i>PALB2</i> has not yet been established [<a class="bk_pop" href="#brca1.REF.jones.2009.217">Jones et al 2009</a>, <a class="bk_pop" href="#brca1.REF.slater.2010.490">Slater et al 2010</a>].</p></div></dd><dt>10. </dt><dd><div id="brca1.TF.3.10"><p class="no_margin">Sixteen individuals with breast cancer, of 207 individuals with Bloom's syndrome reported in Bloom's Syndrome Registry</p></div></dd><dt>11. </dt><dd><div id="brca1.TF.3.11"><p class="no_margin">Seven of 248 neoplasms reported in individuals with Werner syndrome [<a class="bk_pop" href="#brca1.REF.lauper.2013.e59709">Lauper et al 2013</a>]</p></div></dd><dt>12. </dt><dd><div id="brca1.TF.3.12"><p class="no_margin">Lifetime risks of ovarian cancer in Lynch syndrome range from 4% to 12%. Unlike ovarian cancer associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>BRCA1</i>/<i>2</i>, those associated with Lynch syndrome are more likely to be endometrioid or clear cell [<a class="bk_pop" href="#brca1.REF.ketabi.2011.462">Ketabi et al 2011</a>].</p></div></dd><dt>13. </dt><dd><div id="brca1.TF.3.13"><p class="no_margin">Breast cancer has been reported in families with Lynch syndrome, but consistent associations have not been demonstrated [<a class="bk_pop" href="#brca1.REF.gruber.2002.1344">Gruber &#x00026; Petersen 2002</a>, <a class="bk_pop" href="#brca1.REF.m_ller.2002.1014">M&#x000fc;ller et al 2002</a>, <a class="bk_pop" href="#brca1.REF.walsh.2010.2214">Walsh et al 2010</a>].</p></div></dd></dl></div></div></div></div><div id="brca1.Management"><h2 id="_brca1_Management_">Management</h2><div id="brca1.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>Individuals who have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRCA1</i> or <i>BRCA2</i> are counseled at the time of disclosure of molecular genetic test results about their options for <a href="#brca1.Surveillance">Surveillance</a> and <a href="#brca1.Prevention_of_Primary_Manifestatio">Prevention of Primary Manifestations</a>.</p></div><div id="brca1.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>National Comprehensive Cancer Network (NCCN) guidelines suggest that women with a <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> could consider bilateral mastectomy as a primary surgical treatment of breast cancer because of their elevated rate of ipsilateral and contralateral breast cancer [<a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCCN Guidelines</a>].</p></div><div id="brca1.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p><b>Breast cancer</b></p><ul><li class="half_rhythm"><div>Consider prophylactic bilateral mastectomy</div></li><li class="half_rhythm"><div>Given the conflicting data on the degree of risk reduction of breast cancer associated with prophylactic oophorectomy, consider discussing the risks and benefits of this approach with a genetics specialist.</div></li><li class="half_rhythm"><div>Chemoprevention. In a retrospective study tamoxifen reduced the risk for breast cancer by 62% among healthy women with a <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> [<a class="bk_pop" href="#brca1.REF.king.2001.2251">King et al 2001</a>]. The sample size, however, was extremely small. In a nested case-control study, tamoxifen use was associated with a 41%-50% reduction in the risk of developing contralateral breast cancer [<a class="bk_pop" href="#brca1.REF.narod.2000.1876">Narod et al 2000</a>, <a class="bk_pop" href="#brca1.REF.metcalfe.2005.222">Metcalfe et al 2005</a>]. There have been no prospective randomized trials of tamoxifen as a chemoprevention agent in women with BRCA1/2 pathogenic variants.</div></li><li class="half_rhythm"><div>Breast feeding for a cumulative total of more than one year reduced the risk for breast cancer [<a class="bk_pop" href="#brca1.REF.jernstr_m.2004.1094">Jernstr&#x000f6;m et al 2004</a>].</div></li></ul><p><b>Ovarian cancer/fallopian tube cancer</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Consider prophylactic oophorectomy, recognizing that completion of childbearing may factor into this decision. Several studies have documented a significant (80%-96%) risk reduction in ovarian cancer following risk-reducing oophorectomy [<a class="bk_pop" href="#brca1.REF.kauff.2002.1609">Kauff et al 2002</a>, <a class="bk_pop" href="#brca1.REF.rebbeck.2002.1616">Rebbeck et al 2002</a>, <a class="bk_pop" href="#brca1.REF.rutter.2003.1072">Rutter et al 2003</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Salpingectomy. Recent advances in understanding the molecular events preceding ovarian cancer have established the fallopian tube as the origin of the majority of high-grade serous ovarian cancers, leading to the consideration of salpingectomy with ovarian retention until the age of natural menopause as the first step in primary prevention. This approach is likely to reduce the health hazards of premature menopause, but its adoption will require prospective data to establish its safety and efficacy [<a class="bk_pop" href="#brca1.REF.daly.2015.342">Daly et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Tubal ligation. A meta-analysis of 13 studies showed a reduction in risk for ovarian cancer of 34% in the general population after tubal ligation [<a class="bk_pop" href="#brca1.REF.cibula.2011.55">Cibula et al 2011</a>]. A meta-analysis of modifiers of risk of cancer in individuals with pathogenic variants in <i>BRCA1</i>/<i>2</i> found a reduction in the risk of ovarian cancer in females with a <i>BRCA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, although study design issues limit the impact of these findings [<a class="bk_pop" href="#brca1.REF.friebel.2014.dju091">Friebel et al 2014</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Oral contraceptive use has been associated with a reduction in ovarian cancer risk of 14% among women who had ever used oral contraceptives and 38% among long-term users [<a class="bk_pop" href="#brca1.REF.whittemore.2004a.1911">Whittemore et al 2004a</a>].</div><div class="half_rhythm">Note: There is no evidence that use of current (after 1975) oral contraceptive formulations increases the risk for early-onset breast cancer for women with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul></div><div id="brca1.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>Significant adverse consequences of tamoxifen treatment included higher rates of endometrial cancer and thromboembolic episodes (including pulmonary embolism) in those individuals who took the medication than in those who did not. Women with a history of thromboembolic disease or with a coagulation disorder should avoid taking tamoxifen. Women on tamoxifen should be counseled to report any abnormal vaginal bleeding immediately to their gynecologist.</p></div><div id="brca1.Surveillance"><h3>Surveillance</h3><p><b>Women</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Monthly breast self-examination</div></li><li class="half_rhythm"><div class="half_rhythm">Clinical breast examination every 6-12 months beginning at age 25</div></li><li class="half_rhythm"><div class="half_rhythm">Annual breast MRI beginning at age 25, or individualized based on family history if a breast cancer diagnosis before age 30 is present</div></li><li class="half_rhythm"><div class="half_rhythm">Annual mammogram beginning at age 30</div></li><li class="half_rhythm"><div class="half_rhythm">Annual transvaginal ultrasound and serum CA-125 concentration beginning at age 35 years (or individualized based on the earliest age of onset in the family) may be considered for those women who have not elected to undergo prophylactic oophorectomy.</div><div class="half_rhythm">Note: Annual pelvic ultrasound and/or CA-125 concentration has not been effective in detecting early-stage ovarian cancer, either in high-risk or average-risk women.</div></li></ul><p><b>Men</b></p><ul><li class="half_rhythm"><div>Breast self-examination training and regular monthly breast self-examination beginning at age 35</div></li><li class="half_rhythm"><div>Annual clinical breast examination beginning at age 35</div></li><li class="half_rhythm"><div>Annual prostate cancer screening beginning at age 45</div></li></ul><p><b>Women and men</b></p><ul><li class="half_rhythm"><div>Screening for melanoma should be individualized based on the family history.</div></li><li class="half_rhythm"><div>Screening of asymptomatic individuals for pancreatic cancer is not generally recommended, but is possible in research settings.</div></li></ul></div><div id="brca1.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>No data specific to individuals with <i>BRCA1</i>/<i>2</i> pathogenic variants are available.</p></div><div id="brca1.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Once a cancer-predisposing <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> has been identified in a family, testing of at-risk relatives can identify those family members who also have the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> variant and thus need increased surveillance and early intervention when a cancer is identified.</p><p>See <a href="#brca1.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="brca1.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several studies currently underway are looking at novel approaches to the treatment of <i>BRCA</i>-associated breast and ovarian cancer. The majority of the studies involve PARP inhibitors, and have led to FDA approval for one of these agents in treatment of recurrent ovarian cancer. Newer studies are exploring the use of PARP inhibitors in other <i>BRCA</i>-associated cancers (e.g., pancreatic cancer). Given the experimental data showing increased sensitivity of BRCA cell lines to platinum-based agents, there is interest in platinum-based regimens for breast cancer in the neoadjuvant, adjuvant, and metastatic setting.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div><div id="brca1.Other"><h3>Other</h3><p><b>Hormone replacement therapy (HRT).</b> General population studies suggest that long-term estrogen replacement therapy in postmenopausal women may increase breast cancer risk, but that short-term use to treat menopausal symptoms does not. However, even relatively short-term combined estrogen plus progestin use was shown to increase the incidence of breast cancers in a randomized, placebo control trial of HRT [<a class="bk_pop" href="#brca1.REF.chlebowski.2003.3243">Chlebowski et al 2003</a>].</p><p>Three observational studies on the impact of HRT on breast cancer risk in <i>BRCA 1</i>/<i>2</i> heterozygotes have been published. <a class="bk_pop" href="#brca1.REF.rebbeck.2005.7804">Rebbeck et al [2005]</a> evaluated breast cancer risk associated with HRT after bilateral prophylactic oophorectomy in a cohort of 462 women with a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and found that HRT of any type after bilateral prophylactic oophorectomy did not significantly alter the reduction in breast cancer risk associated with the surgery. The postoperative follow up was 3.6 years. It was concluded that short-term HRT does not substantially increase the risk for breast cancer in women with a <i>BRCA1</i> or <i>BRCA2</i> germline pathogenic variant. A subsequent study of expanded data from this cohort included 1299 women with a mean follow-up of 5.4 years. There was no increase in breast cancer risk, and a significant decrease in breast cancer risk was found among <i>BRCA1</i> heterozygotes [<a class="bk_pop" href="#brca1.REF.domchek.2011">Domchek et al 2011</a>]. In another matched case-control study of 472 postmenopausal women with a <i>BRCA1</i> pathogenic variant, the use of HRT was associated with a reduction in breast cancer risk [<a class="bk_pop" href="#brca1.REF.eisen.2008.1361">Eisen et al 2008</a>]. Finally, a case-control study of 432 matched pairs with a mean follow up of 4.3 years also found a decrease in the risk for breast cancer in <i>BRCA1</i> heterozygotes [<a class="bk_pop" href="#brca1.REF.kotsopoulos.2016.365">Kotsopoulos et al 2016</a>]. Taken together, these studies support the short-term use of HRT among <i>BRCA1</i>/<i>2</i> heterozygotes who have undergone surgical menopause.</p></div></div><div id="brca1.Genetic_Counseling"><h2 id="_brca1_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="brca1.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>BRCA1</i> and <i>BRCA2</i> hereditary breast and ovarian cancer syndrome (HBOC) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="brca1.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <i>BRCA1/2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></b></p><ul><li class="half_rhythm"><div>The vast majority of individuals with a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> in <i>BRCA1</i> or <i>BRCA2</i> have inherited it from a parent.</div></li><li class="half_rhythm"><div>The parent with the variant may or may not have had a cancer diagnosis depending on the following variables:</div><ul><li class="half_rhythm"><div>Penetrance of the variant</div></li><li class="half_rhythm"><div>Gender of the parent</div></li><li class="half_rhythm"><div>Age of the parent</div></li><li class="half_rhythm"><div>Cancer risk reduction in the parent as a result of screening or prophylactic surgeries</div></li><li class="half_rhythm"><div>Early death of the parent</div></li></ul></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to both parents of an individual with a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to determine which side of the family is at risk. Generally, the pattern of cancers seen in the family usually guides which parent is tested first.</div></li><li class="half_rhythm"><div>Rarely, neither parent will be identified as having the <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. In the years since the discovery of <i>BRCA1</i> and <i>BRCA2</i>, <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> variants have been reported, but the rate appears to be extremely low in these two genes (&#x02264;5%) based on the few studies performed to date [<a class="bk_pop" href="#brca1.REF.hansen.2008.58">Hansen et al 2008</a>, <a class="bk_pop" href="#brca1.REF.marshall.2009.427">Marshall et al 2009</a>, <a class="bk_pop" href="#brca1.REF.diez.2010.221">Diez et al 2010</a>, <a class="bk_pop" href="#brca1.REF.garciacasado.2011.134">Garcia-Casado et al 2011</a>, <a class="bk_pop" href="#brca1.REF.kwong.2011.233">Kwong et al 2011</a>, <a class="bk_pop" href="#brca1.REF.zhang.2011.97">Zhang et al 2011</a>, <a class="bk_pop" href="#brca1.REF.de_leeneer.2012.87">De Leeneer et al 2012</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>
<b>with a <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></b></p><ul><li class="half_rhythm"><div>The risk to full sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents: the risk that a sib of an index case will inherit the <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 50% if one parent has the <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a>.</div></li><li class="half_rhythm"><div>The risk of developing cancer, however, depends on numerous variables including the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the gender and age of the individual.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> The offspring of an individual identified as having a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant have a 50% chance of inheriting the variant. The risk of developing cancer, however, depends on numerous variables including the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the pathogenic variant and the gender and age of the individual.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <i>BRCA1</i>/<i>2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> The risk to other family members depends on the status of the proband's parents. If a parent has a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a>, his or her family members are at risk. Their exact risk depends on their position in the <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a>.</p></div><div id="brca1.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#brca1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i> (although rare, <i>de novo</i> variants in both <i>BRCA1</i> and <i>BRCA2</i> have been reported). However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for the determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Genetic cancer risk assessment and counseling.</b> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, see <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</a> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p><p><b>At-risk asymptomatic adult relatives.</b> In general, relatives of an individual who has a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be counseled regarding their risk of having inherited the same variant, their options for <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, their cancer risk, and recommendations for cancer screening (see <a href="#brca1.Surveillance">Surveillance</a>) and prophylactic surgery (see <a href="#brca1.Prevention_of_Primary_Manifestatio">Prevention of Primary Manifestations</a>).</p><p>At-risk adult relatives who have not inherited the cancer-predisposing <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are presumed to be at or above the general population risk of developing cancer, depending on personal risk factors. For example, a female at-risk relative who does not have the family-specific <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may still be at an elevated risk for breast cancer based on a breast biopsy history that revealed atypical ductal hyperplasia.</p><p>For family members determined to be at general population risk of developing cancer, appropriate cancer screening such as that recommended by the <a href="http://www.cancer.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">American Cancer Society</a> or the <a href="http://www.nccn.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">National Comprehensive Cancer Network</a> (NCCN) for individuals of average risk is recommended. Note: This presumption cannot apply to individuals who did not have an identifiable <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> if the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in the family either has not undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>BRCA1</i> or <i>BRCA2</i> or did not have an identified <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant.</p><p><b>Testing of asymptomatic individuals younger than age 18 years.</b> In general, genetic testing for HBOC is not recommended for at-risk individuals younger than age 18 years. Guidelines established jointly by the American College of Medical Genetics and the American Society of Human Genetics state that predictive genetic testing should only be performed in individuals younger than age 18 years when it will affect their medical management. Management for HBOC-related cancer is typically recommended to begin at approximately age 25, which is why it is recommended that the decision to test be postponed until an individual reaches adulthood and can make an independent decision. It is important to note, however, that since there are rare reported cases of individuals with HBOC diagnosed with cancer at very young ages, it is recommended that screening be individualized based on the earliest diagnosis in the family.</p><p>For more information, see also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="brca1.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for HBOC are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="brca1.Resources"><h2 id="_brca1_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Breast Cancer Information Core</b></div><div><i>Breast cancer resources</i></div><div>National Human Genome Research Institute (NHGRI)</div><div><a href="http://research.nhgri.nih.gov/bic/resources.shtml" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">research.nhgri.nih.gov/bic/resources.shtml</a></div></li><li class="half_rhythm"><div><b>Bright Pink</b></div><div>670 North Clark Street</div><div>Suite 2</div><div>Chicago IL 60654</div><div><a href="http://www.brightpink.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.brightpink.org</a></div></li><li class="half_rhythm"><div><b>FORCE: Facing Our Risk of Cancer Empowered</b></div><div><i>A discussion forum specifically for women who are at a high risk of developing ovarian cancer or breast cancer</i></div><div>16057 Tampa Palms Boulevard West</div><div>PMB #373</div><div>Tampa FL 33647</div><div><b>Phone:</b> 866-288-7475 (toll-free)</div><div><b>Fax:</b> 954-827-2200</div><div><b>Email:</b> info@facingourrisk.org</div><div><a href="http://www.facingourrisk.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.facingourrisk.org</a></div></li><li class="half_rhythm"><div><b>Gilda's Club Worldwide</b></div><div>48 Wall Street</div><div>11th Floor</div><div>New York NY 10005</div><div><b>Phone:</b> 888-445-3248 (toll-free)</div><div><b>Fax:</b> 917-305-0549</div><div><b>Email:</b> info@gildasclub.org</div><div><a href="http://www.cancersupportcommunity.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancersupportcommunity.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Hereditary%20Breast%20and%20Ovarian%20Cancer%20syndrome&#x00026;parent=Disease%20Risk&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary Breast and Ovarian Cancer</a></div></li><li class="half_rhythm"><div><b>National Breast and Ovarian Cancer Centre (NBOCC)</b></div><div>Locked Bag 3</div><div>Strawberry Hills New South Wales 2012</div><div>Australia</div><div><b>Phone:</b> +61 2 9357 9400</div><div><b>Fax:</b> +61 2 9357 9477</div><div><b>Email:</b> directorate@nbocc.org.au</div><div><a href="http://www.nbocc.org.au" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbocc.org.au</a></div></li><li class="half_rhythm"><div><b>National Breast Cancer Coalition (NBCC)</b></div><div><i>An advocacy group seeking public policy change to benefit breast cancer patients and survivors</i></div><div>1101 17th Street Northwest</div><div>Suite 1300</div><div>Washington DC 20036</div><div><b>Phone:</b> 800-622-2838 (toll-free); 202-296-7477</div><div><b>Fax:</b> 202-265-6854</div><div><b>Email:</b> info@stopbreastcancer.org</div><div><a href="http://www.stopbreastcancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.stopbreastcancer.org</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov/cancertopics/types/breast" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast Cancer</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Genetics of Breast and Ovarian Cancer (PDQ)</a></div></li><li class="half_rhythm"><div><b>National Ovarian Cancer Coalition (NOCC)</b></div><div>2501 Oak Lawn Avenue</div><div>Suite 435</div><div>Dallas TX 75219</div><div><b>Phone:</b> 888-682-7426 (Toll-free Helpline); 214-273-4200</div><div><b>Fax:</b> 214-273-4201</div><div><b>Email:</b> nocc@ovarian.org</div><div><a href="http://www.ovarian.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ovarian.org</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22168/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast and ovarian cancer</a></div></li><li class="half_rhythm"><div><b>Probability of Breast Cancer in American Women</b></div><div>National Cancer Institute Public Inquiries Office</div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Probability of Breast Cancer in American Women</a></div></li><li class="half_rhythm"><div><b>Sharsheret</b></div><div><i>Linking young Jewish women in their fight against breast cancer</i></div><div>1086 Teaneck Road</div><div>Suite 3A</div><div>Teaneck NJ 07666</div><div><b>Phone:</b> 866-474-2774 (toll-free); 201-833-2341</div><div><b>Email:</b> info@sharsheret.org</div><div><a href="http://www.sharsheret.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sharsheret.org</a></div></li><li class="half_rhythm"><div><b>Susan G. Komen Breast Cancer Foundation</b></div><div><i>Information, referrals to treatment centers. Answers questions from recently diagnosed women and provides emotional support. Funds research programs for women who do not have adequate medical service and support.</i></div><div>5005 LBJ Freeway</div><div>Suite 250</div><div>Dallas TX 75244</div><div><b>Phone:</b> 877-465-6636 (Toll-free Helpline)</div><div><b>Fax:</b> 972-855-1605</div><div><b>Email:</b> helpline@komen.org</div><div><a href="http://ww5.komen.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ww5.komen.org</a></div></li><li class="half_rhythm"><div><b>American Cancer Society (ACS)</b></div><div>250 Williams Street Northwest</div><div>Atlanta GA 30303</div><div><b>Phone:</b> 800-227-2345 (toll-free 24/7); 866-228-4327 (toll-free 24/7 TTY)</div><div><a href="http://www.cancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.org</a></div></li><li class="half_rhythm"><div><b>CancerCare</b></div><div>275 Seventh Avenue</div><div>22nd Floor</div><div>New York NY 10001</div><div><b>Phone:</b> 800-813-4673 (toll-free); 212-712-8400 (administrative)</div><div><b>Fax:</b> 212-712-8495</div><div><b>Email:</b> info@cancercare.org</div><div><a href="http://www.cancercare.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancercare.org</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.gov</a></div></li><li class="half_rhythm"><div><b>National Coalition for Cancer Survivorship (NCCS)</b></div><div><i>A consumer organization that advocates on behalf of all people with cancer</i></div><div>8455 Colesville Road</div><div>Suite 930</div><div>Silver Spring MD 20910</div><div><b>Phone:</b> 877-622-7937 (toll-free); 301-650-9127</div><div><b>Fax:</b> 301-565-9670</div><div><b>Email:</b> info@canceradvocacy.org</div><div><a href="http://www.canceradvocacy.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.canceradvocacy.org</a></div></li><li class="half_rhythm"><div><b>Familial Ovarian Cancer Registry</b></div><div>Roswell Park Cancer Institute</div><div>Elm and Carlton Streets</div><div>Buffalo NY 14263</div><div><b>Phone:</b> 716-845-4503</div><div><a href="http://ovariancancer.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ovariancancer.com</a></div></li><li class="half_rhythm"><div><b>Prospective Registry of MultiPlex Testing (PROMPT)</b></div><div><i>PROMPT is an online research registry for patients and families who have undergone multiplex genetic testing and were found to have a genetic variation which may be linked to an increased risk of having cancer.</i></div><div><a href="https://connect.patientcrossroads.org/?org=prompt" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PROMPT</a></div></li></ul></div><div id="brca1.Molecular_Genetics"><h2 id="_brca1_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="brca1.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_brca1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_brca1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_brca1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_brca1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_brca1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_brca1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_brca1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/672" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BRCA1</i></a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=672" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q21<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P38398" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast cancer type 1 susceptibility protein</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/BRCA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA1 homepage - LOVD</a><br /><a href="http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Database of BRCA1 and BRCA2 sequence variants that have been clinically reclassified by a quantitative integrated evaluation</a><br /><a href="https://research.nhgri.nih.gov/bic/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast Cancer Information Core (BRCA1)</a><br /><a href="https://lovd.nl/BRCA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA1 @ ZAC-GGM</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRCA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA1</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRCA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA1</a></td></tr><tr><td headers="hd_b_brca1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/675" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BRCA2</i></a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=675" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">13q13<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P51587" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast cancer type 2 susceptibility protein</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2 homepage - LOVD</a><br /><a href="http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Database of BRCA1 and BRCA2 sequence variants that have been clinically reclassified using a quantitative integrated evaluation</a><br /><a href="https://research.nhgri.nih.gov/bic/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast Cancer Information Core (BRCA2)</a><br /><a href="http://www.rockefeller.edu/fanconi/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCD1 - BRCA2)</a><br /><a href="https://lovd.nl/BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2 @ ZAC-GGM</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2</a></td><td headers="hd_b_brca1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRCA2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="brca1.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="brca1.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer (<a href="/omim/113705,114480,600185,604370,612555" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/113705" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">113705</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BREAST CANCER 1 GENE; BRCA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/114480" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">114480</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BREAST CANCER</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600185" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600185</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA2 GENE; BRCA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604370" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604370</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612555" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612555</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2</td></tr></tbody></table></div></div><p><b><i>BRCA1</i></b></p><p><b>Gene structure.</b>
<i>BRCA1</i> spans more than 80 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA and encodes a 7.8-kb transcript composed of 24 coding exons [<a class="bk_pop" href="#brca1.REF.miki.1994.66">Miki et al 1994</a>, <a class="bk_pop" href="#brca1.REF.deng.2006.1416">Deng 2006</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1247/#brca1.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 1800 pathogenic variants have been identified in <i>BRCA1</i>. While a small number of these variants have been identified repeatedly in unrelated families, the vast majority have not been reported in more than a few families. Overall, among individuals undergoing <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>BRCA1</i> and <i>BRCA2</i>, approximately 2.9% will have a variant of uncertain clinical significance [<a class="bk_pop" href="#brca1.REF.eggington.2012">Eggington et al 2012</a>] &#x02013; a proportion that has declined significantly over the past ten years. (For more information, see <a href="/books/NBK1247/#brca1.molgen.TA">Table A</a>.)</p><p><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> variant.</b> p.Arg1699Gln is established to be a reduced penetrance variant in <i>BRCA1</i> [<a class="bk_pop" href="#brca1.REF.spurdle.2012.525">Spurdle et al 2012</a>]. Data from functional assays were ambiguous for deficiency across multiple assays. Thus, this <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was determined to be associated with intermediate risk for breast and ovarian cancer, highlighting challenges for risk modeling and clinical management of individuals of this and other potential moderate-risk variants.</p><div id="brca1.T.selected_brca1_pathogenic_varian" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>BRCA1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.T.selected_brca1_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.T.selected_brca1_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.68_69delAG<br />(185delAG or 187delAG)</td><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu23ValfsTer17</td><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/237757283" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_007294<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/6552299" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_009225<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5096G&#x0003e;A</td><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1699Gln</td></tr><tr><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5266dupC<br />(5385insC or 5382insC)</td><td headers="hd_h_brca1.T.selected_brca1_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln1756ProfsTer74</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society <a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">(varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="brca1.TF.4.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>BRCA1</i> codes for a 220-kd protein of 1863 amino acids. The breast cancer type 1 susceptibility protein (BRCA1) is a phosphoprotein normally located in the nucleus [<a class="bk_pop" href="#brca1.REF.chen.1996.3168">Chen et al 1996</a>]. Its functional domains include:</p><ul><li class="half_rhythm"><div>A RING finger <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> near the N-terminus; may facilitate both protein-protein (BRCA1 / BARD1) and protein-DNA interactions [<a class="bk_pop" href="#brca1.REF.boddy.1994.198">Boddy et al 1994</a>]</div></li><li class="half_rhythm"><div>Two nuclear localization signals located in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11</div></li><li class="half_rhythm"><div>An "SQ" cluster between p.1280 and p.1524</div></li><li class="half_rhythm"><div>A BRCT <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> at the C-terminus</div></li></ul><p>BRCA1 interacts with several proteins involved in cellular pathways, including cell-cycle progression, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> transcription regulation, DNA damage response, and ubiquitination [<a class="bk_pop" href="#brca1.REF.deng.2006.1416">Deng 2006</a>, <a class="bk_pop" href="#brca1.REF.rosen.2006.175">Rosen et al 2006</a>].</p><p>The BRCA1/BARD1 protein complex enhances ubiquitin ligase activity, which is associated with the regulation of centrosome function and involved in DNA repair and cell cycle regulation [<a class="bk_pop" href="#brca1.REF.sankaran.2006.4100">Sankaran et al 2006</a>, <a class="bk_pop" href="#brca1.REF.bork.1997.68">Bork et al 1997</a>, <a class="bk_pop" href="#brca1.REF.callebaut.1997.25">Callebaut &#x00026; Mornon 1997</a>].</p><p>BRCA1 is expressed in most tissues and cell types analyzed, suggesting that it is not the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression pattern that leads to the tissue-restricted <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of breast and ovarian cancer. The transcription of <i>BRCA1</i> is induced late in the G<sub>1</sub> phase of the cell cycle and remains elevated during the S phase, indicating some role in DNA synthesis [<a class="bk_pop" href="#brca1.REF.gudas.1996.717">Gudas et al 1996</a>, <a class="bk_pop" href="#brca1.REF.rajan.1996.13078">Rajan et al 1996</a>]. A variety of evidence now points to the breast cancer type 1 susceptibility protein as being directly involved in the DNA repair process.</p><p>BRCA1 colocalizes with BRCA2 and RAD51 at sites of DNA damage and activates RAD51-mediated homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> repair of DNA double-strand breaks [<a class="bk_pop" href="#brca1.REF.cousineau.2005.11384">Cousineau et al 2005</a>]. One of the targets of <i>BRCA1</i> transcriptional activation appears to be the p21 cyclin-dependent kinase inhibitor, itself a potent suppressor of growth at the G<sub>1</sub>/S checkpoint [<a class="bk_pop" href="#brca1.REF.somasundaram.1997.187">Somasundaram et al 1997</a>, <a class="bk_pop" href="#brca1.REF.ouchi.1998.2302">Ouchi et al 1998</a>].</p><p>Complete loss of <i>Brca1</i> in the mouse is embryonic lethal, characterized by a lack of cell proliferation [<a class="bk_pop" href="#brca1.REF.hakem.1996.1009">Hakem et al 1996</a>, <a class="bk_pop" href="#brca1.REF.ludwig.1997.1226">Ludwig et al 1997</a>]. Cells derived from mouse embryos lacking <i>Brca1</i> are defective in their repair of DNA damage [<a class="bk_pop" href="#brca1.REF.gowen.1998.1009">Gowen et al 1998</a>]. Interestingly, <i>Brca1</i> knockout mice can be partially rescued by crossing with a <i>Tp53</i> knockout strain, suggesting that these genes interact with the <a href="/books/n/gene/li-fraumeni/"><i>TP53</i></a>-mediated DNA damage checkpoint [<a class="bk_pop" href="#brca1.REF.brugarolas.1997.721">Brugarolas &#x00026; Jacks 1997</a>]. Therefore, the available evidence indicates that <i>BRCA1</i> serves as a "caretaker," like <i>TP53</i>, helping to maintain <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> integrity [<a class="bk_pop" href="#brca1.REF.zhang.1998.433">Zhang et al 1998</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most <i>BRCA1</i> pathogenic variants lead to frameshifts resulting in a missing or non-functional protein. In cancers from individuals with a <i>BRCA1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is deleted or inactivated, resulting in somatic inactivation of <i>BRCA1</i>. This strongly suggests that <i>BRCA1</i> is a tumor-suppressor gene whose loss of function can result in <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> instability, resulting in a high susceptibility to malignant transformation [<a class="bk_pop" href="#brca1.REF.smith.1992.128">Smith et al 1992</a>, <a class="bk_pop" href="#brca1.REF.deng.2006.1416">Deng 2006</a>]. Additional evidence in support of a tumor suppressor function is that overexpression of the BRCA1 protein leads to growth suppression similar to that seen with the classic tumor suppressors <a href="/books/n/gene/li-fraumeni/"><i>TP53</i></a> and the <a href="/books/n/gene/retinoblastoma/">retinoblastoma</a> gene (<i>RB1</i>) [<a class="bk_pop" href="#brca1.REF.holt.1996.298">Holt et al 1996</a>]. Loss of function of <i>BRCA1</i> results in defects in DNA repair, defects in transcription, abnormal centrosome <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>, defective G2/M cell-cycle checkpoint regulation, impaired spindle checkpoint, and <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> damage [<a class="bk_pop" href="#brca1.REF.brodie.2001.s18">Brodie &#x00026; Deng 2001</a>, <a class="bk_pop" href="#brca1.REF.deng.2002.171">Deng 2002</a>, <a class="bk_pop" href="#brca1.REF.venkitaraman.2002.171">Venkitaraman 2002</a>].</p><p><b><i>BRCA2</i></b></p><p><b>Gene structure.</b>
<i>BRCA2</i> encodes a 10.4-kb transcript composed of 27 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1247/#brca1.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> As with <i>BRCA1</i>, more than 1800 pathogenic variants in <i>BRCA2</i> have been identified. (For more information, see <a href="/books/NBK1247/#brca1.molgen.TA">Table A</a>.) Overall, approximately 2.9% of individuals undergoing <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>BRCA1</i> and <i>BRCA2</i> will have a variant of uncertain clinical significance [<a class="bk_pop" href="#brca1.REF.eggington.2012">Eggington et al 2012</a>] &#x02013; a proportion that has declined significantly over the past ten years (see <a href="http://research.nhgri.nih.gov/bic/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NHGRI-BIC Database</a>). In the future, some of these will likely prove to be benign variants without clinical significance, while others may be associated with an increased cancer risk.</p><p><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> variant.</b> There is evidence that p.Lys3326Ter is associated with risk of developing breast and ovarian cancers independent of other pathogenic variants in <i>BRCA2</i>, although penetrance is reduced. This was demonstrated through a large case-control study based on an international consortium of patients with cancer. Further studies are needed to determine the biologic mechanism of action responsible for these associations [<a class="bk_pop" href="#brca1.REF.meeks.2015.djv315">Meeks et al 2015</a>].</p><div id="brca1.T.selected_brca2_pathogenic_varian" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Selected <i>BRCA2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1247/table/brca1.T.selected_brca2_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__brca1.T.selected_brca2_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.771_775delTCAAA<br />(999del5)</td><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn257LysfsTer17</td><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/119395733" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000059<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/119395734" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000050<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5946delT<br />(6174delT)</td><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser1982ArgfsTer22</td></tr><tr><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.9976A&#x0003e;T</td><td headers="hd_h_brca1.T.selected_brca2_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys3326Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="brca1.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>BRCA2</i> encodes a 380-kd protein of 3,418 amino acids. Eight 30-40 residue motifs found in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 mediate the binding of breast cancer type 2 susceptibility protein (BRCA2) to RAD51. BRCA2 is a phosphoprotein normally located in the nucleus [<a class="bk_pop" href="#brca1.REF.bertwistle.1997.5485">Bertwistle et al 1997</a>]. BRCA2 protein has no recognizable protein motifs and no apparent relation to the breast cancer type 1 susceptibility protein.</p><p>Like <i>BRCA1</i>, <i>BRCA2</i> is expressed in most tissues and cell types analyzed, indicating that <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression does not account for the tissue-restricted <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of breast and ovarian cancer. <i>BRCA2</i> transcription is induced late in the G<sub>1</sub> phase of the cell cycle and remains elevated during the S phase, indicating some role in DNA synthesis [<a class="bk_pop" href="#brca1.REF.rajan.1996.13078">Rajan et al 1996</a>, <a class="bk_pop" href="#brca1.REF.vaughn.1996.4590">Vaughn et al 1996</a>].</p><p><i>BRCA2</i> appears to be involved in the DNA repair process. The breast cancer type 2 susceptibility protein interacts with the RAD51 protein, a key component in homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> and double-strand break repair [<a class="bk_pop" href="#brca1.REF.sharan.1997.804">Sharan et al 1997</a>, <a class="bk_pop" href="#brca1.REF.wong.1997.31941">Wong et al 1997</a>]. Through this interaction, BRCA2 regulates the availability and activity of RAD51, which coats single-strand DNA to form a nucleoprotein filament that invades and pairs with a homologous DNA duplex to initiate strand exchange [<a class="bk_pop" href="#brca1.REF.venkitaraman.2002.171">Venkitaraman 2002</a>].</p><p>Complete loss of <i>Brca2</i> in the mouse is embryonic lethal, characterized by a lack of cell proliferation [<a class="bk_pop" href="#brca1.REF.ludwig.1997.1226">Ludwig et al 1997</a>, <a class="bk_pop" href="#brca1.REF.sharan.1997.804">Sharan et al 1997</a>, <a class="bk_pop" href="#brca1.REF.suzuki.1997.1242">Suzuki et al 1997</a>]. Cells derived from mouse embryos lacking <i>Brca2</i> are defective in their repair of DNA damage [<a class="bk_pop" href="#brca1.REF.connor.1997.423">Connor et al 1997</a>, <a class="bk_pop" href="#brca1.REF.chen.1998b.5287">Chen et al 1998b</a>] and are hypersensitive to radiation and radiomimetics [<a class="bk_pop" href="#brca1.REF.abbott.1998.978">Abbott et al 1998</a>, <a class="bk_pop" href="#brca1.REF.biggs.1998.951">Biggs &#x00026; Bradley 1998</a>, <a class="bk_pop" href="#brca1.REF.chen.1998a.317">Chen et al 1998a</a>, <a class="bk_pop" href="#brca1.REF.morimatsu.1998.3441">Morimatsu et al 1998</a>] &#x02013; findings that may have implications for both mammographic screening and treatment modalities. Finally, <i>Brca2</i> knockout mice can be partially rescued by crossing with a <i>Tp53</i> knockout strain, suggesting that these genes interact with the <i>TP53</i> -mediated DNA damage checkpoint [<a class="bk_pop" href="#brca1.REF.brugarolas.1997.721">Brugarolas &#x00026; Jacks 1997</a>]. Therefore, the available evidence indicates that <i>BRCA2</i> is a "caretaker," like <i>TP53</i>, serving to maintain <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> integrity [<a class="bk_pop" href="#brca1.REF.zhang.1998.433">Zhang et al 1998</a>]. It is likely that <i>BRCA2</i> will eventually be implicated in a variety of cellular processes, only some of which will be related to their role in the etiology of breast and ovarian cancer.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most <i>BRCA2</i> pathogenic variants reported to date consist of frameshift deletions, insertions, or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants that predict premature truncation of protein transcription, consistent with the loss of function that is expected with clinically significant variants of tumor suppressor genes. Cells lacking BRCA2 are deficient in the repair of double-strand DNA breaks, as reflected in a hypersensitivity to ionizing radiation [<a class="bk_pop" href="#brca1.REF.venkitaraman.2001.3591">Venkitaraman 2001</a>].</p></div><div id="brca1.References"><h2 id="_brca1_References_">References</h2><div id="brca1.Published_GuidelinesConsensus_Stat"><h3>Published Guidelines/Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="brca1.REF1">NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian.</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF2">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <a href="http://jco.ascopubs.org/content/28/5/893.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 3-20-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF3">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 3-20-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF4">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2017. Accessed 3-20-18.</div></li></ul></div><div id="brca1.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.abbott.1998.978">Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. <span><span class="ref-journal">J Natl Cancer Inst. </span>1998;<span class="ref-vol">90</span>:978–85.</span> [<a href="/pubmed/9665145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9665145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.alsop.2012.2654">Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <span><span class="ref-journal">J Clin Oncol. </span>2012;<span class="ref-vol">30</span>:2654–63.</span> [<a href="/pmc/articles/PMC3413277/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3413277</span></a>] [<a href="/pubmed/22711857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22711857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.american_society_of_clinical_oncology.2003.2397">American Society of Clinical Oncology.  Policy statement update: genetic testing for cancer susceptibility. <span><span class="ref-journal">J Clin Oncol. </span>2003;<span class="ref-vol">21</span>:2397–406.</span> [<a href="/pubmed/12692171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12692171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.anglian_breast_cancer_study_group.2000.1301">Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series ofbreast cancer cases. <span><span class="ref-journal">Br J Cancer. </span>2000;<span class="ref-vol">83</span>:1301–8.</span> [<a href="/pmc/articles/PMC2408797/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2408797</span></a>] [<a href="/pubmed/11044354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11044354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.antoniou.2014.497">Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylk&#x000e4;s K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittom&#x000e4;ki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">371</span>:497–506.</span> [<a href="/pmc/articles/PMC4157599/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4157599</span></a>] [<a href="/pubmed/25099575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25099575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.antoniou.2004.1580">Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. <span><span class="ref-journal">Br J Cancer. </span>2004;<span class="ref-vol">91</span>:1580–90.</span> [<a href="/pmc/articles/PMC2409934/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2409934</span></a>] [<a href="/pubmed/15381934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15381934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.beiner.2007.7">Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, Lynch HT, Friedman E, Sun P, Narod SA, et al.  The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. <span><span class="ref-journal">Gynecol Oncol. </span>2007;<span class="ref-vol">104</span>:7–10.</span> [<a href="/pubmed/16962648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16962648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.bernstein.2006.348">Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R, Olson ER, Wolitzer AL, Seminara D, Whittemore AS, Concannon P. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the breast cancer family registry. <span><span class="ref-journal">Cancer Epidemiol Biomarkers Prev. </span>2006;<span class="ref-vol">15</span>:348–52.</span> [<a href="/pubmed/16492927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16492927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.bertwistle.1997.5485">Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S, Crompton MR, Marshall CJ, Ashworth A. Nuclear location and cell cycle regulation of the BRCA2 protein. <span><span class="ref-journal">Cancer Res. </span>1997;<span class="ref-vol">57</span>:5485–8.</span> [<a href="/pubmed/9407955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9407955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.biggs.1998.951">Biggs PJ, Bradley A. A step toward genotype-based therapeutic regimens for breast cancer in patients with BRCA2 mutations? <span><span class="ref-journal">J Natl Cancer Inst. </span>1998;<span class="ref-vol">90</span>:951–3.</span> [<a href="/pubmed/9665137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9665137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.boddy.1994.198">Boddy MN, Freemont PS, Borden KL. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. <span><span class="ref-journal">Trends Biochem Sci. </span>1994;<span class="ref-vol">19</span>:198–9.</span> [<a href="/pubmed/8048160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8048160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.bolton.2012.382">Bolton KL, Chenevix-Trench G, Gob C, Sadetzke S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benetiz J, Garcia MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma EDK, Lazaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SF, Jjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg A, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PDP, et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. <span><span class="ref-journal">JAMA. </span>2012;<span class="ref-vol">307</span>:382–90.</span> [<a href="/pmc/articles/PMC3727895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3727895</span></a>] [<a href="/pubmed/22274685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22274685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.bordeleau.2010.13">Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">119</span>:13–24.</span> [<a href="/pubmed/19789974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19789974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.bork.1997.68">Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. <span><span class="ref-journal">FASEB J. </span>1997;<span class="ref-vol">11</span>:68–76.</span> [<a href="/pubmed/9034168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9034168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.breast_cancer_linkage_consortium.1999.1310">Breast Cancer Linkage Consortium.  Cancer risks in BRCA2 mutation carriers. <span><span class="ref-journal">J Natl Cancer Inst. </span>1999;<span class="ref-vol">91</span>:1310–6.</span> [<a href="/pubmed/10433620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10433620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.brodie.2001.s18">Brodie SG, Deng CX. BRCA1-associated tumorigenesis: what have we learned from knockout mice? <span><span class="ref-journal">Trends Genet. </span>2001;<span class="ref-vol">17</span>:S18–22.</span> [<a href="/pubmed/11585672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11585672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.brookswilson.2004.508">Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:508–17.</span> [<a href="/pmc/articles/PMC1735838/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735838</span></a>] [<a href="/pubmed/15235021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15235021</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.brugarolas.1997.721">Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. <span><span class="ref-journal">Nat Med. </span>1997;<span class="ref-vol">3</span>:721–2.</span> [<a href="/pubmed/9212093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9212093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.bubien.2013.255">Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F, et al.  High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. <span><span class="ref-journal">J Med Genet. </span>2013;<span class="ref-vol">50</span>:255–63.</span> [<a href="/pubmed/23335809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23335809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.callebaut.1997.25">Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. <span><span class="ref-journal">FEBS Lett. </span>1997;<span class="ref-vol">400</span>:25–30.</span> [<a href="/pubmed/9000507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9000507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.casadei.2011.2222">Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. <span><span class="ref-journal">Cancer Res. </span>2011;<span class="ref-vol">71</span>:2222–9.</span> [<a href="/pmc/articles/PMC3059378/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3059378</span></a>] [<a href="/pubmed/21285249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21285249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.casey.2005.457">Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. <span><span class="ref-journal">Gynecol Oncol. </span>2005;<span class="ref-vol">97</span>:457–67.</span> [<a href="/pubmed/15863145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15863145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.chek2_breast_cancer_casecontrol_consortium.2004.1175">CHEK2 Breast Cancer Case-Control Consortium.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:1175–82.</span> [<a href="/pmc/articles/PMC1182081/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182081</span></a>] [<a href="/pubmed/15122511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15122511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.chen.1998a.317">Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. <span><span class="ref-journal">Mol Cell. </span>1998a;<span class="ref-vol">2</span>:317–28.</span> [<a href="/pubmed/9774970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9774970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.chen.1998b.5287">Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1998b;<span class="ref-vol">95</span>:5287–92.</span> [<a href="/pmc/articles/PMC20253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC20253</span></a>] [<a href="/pubmed/9560268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9560268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.chen.2006.863">Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. <span><span class="ref-journal">J Clin Oncol. </span>2006;<span class="ref-vol">24</span>:863–71.</span> [<a href="/pmc/articles/PMC2323978/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2323978</span></a>] [<a href="/pubmed/16484695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16484695</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.chen.1996.3168">Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. <span><span class="ref-journal">Cancer Res. </span>1996;<span class="ref-vol">56</span>:3168–72.</span> [<a href="/pubmed/8764100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8764100</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.chlebowski.2003.3243">Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. <span><span class="ref-journal">JAMA. </span>2003;<span class="ref-vol">289</span>:3243–53.</span> [<a href="/pubmed/12824205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12824205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.cibula.2011.55">Cibula D, Widschwendter M, Majek O, Dusek L. tubal ligation and the risk of ovarian cancer: review and meta-analysis. <span><span class="ref-journal">Hum Reprod Update. </span>2011;<span class="ref-vol">17</span>:55–67.</span> [<a href="/pubmed/20634209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20634209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.connor.1997.423">Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. <span><span class="ref-journal">Nat Genet. </span>1997;<span class="ref-vol">17</span>:423–30.</span> [<a href="/pubmed/9398843" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9398843</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.couch.2015.304">Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. <span><span class="ref-journal">J Clin Oncol. </span>2015;<span class="ref-vol">33</span>:304–11.</span> [<a href="/pmc/articles/PMC4302212/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4302212</span></a>] [<a href="/pubmed/25452441" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25452441</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.cousineau.2005.11384">Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. <span><span class="ref-journal">Cancer Res. </span>2005;<span class="ref-vol">65</span>:11384–91.</span> [<a href="/pubmed/16357146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16357146</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.daly.2015.342">Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH. Salpingectomy as a means to reduce ovarian cancer risk. <span><span class="ref-journal">Cancer Prev Res (Phila). </span>2015;<span class="ref-vol">8</span>:342–8.</span> [<a href="/pmc/articles/PMC4417454/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4417454</span></a>] [<a href="/pubmed/25586903" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25586903</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.dann.2012.677">Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, Lanchbury JS, Kirvak TC. BRCA1/2 muatations and expression: resonse to platinum chemogherapy in patients with advanced stage epithelial ovarian cancer. <span><span class="ref-journal">Gynecol Oncol. </span>2012;<span class="ref-vol">125</span>:677–82.</span> [<a href="/pubmed/22406760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22406760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.de_la_hoya.2003.503">de la Hoya M, D&#x000ed;ez O, P&#x000e9;rez-Segura P, Godino J, Fern&#x000e1;ndez JM, Sanz J, Alonso C, Baiget M, D&#x000ed;az-Rubio E, Cald&#x000e9;s T. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:503–10.</span> [<a href="/pmc/articles/PMC1735524/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735524</span></a>] [<a href="/pubmed/12843322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12843322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.de_leeneer.2012.87">De Leeneer K, Coene I, Crombez B, Simkens J, van den Broecke R, Bols A, Stragier B, Vanhoutte I, De Paepe A, Poppe B, Claes K. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2012;<span class="ref-vol">132</span>:87–95.</span> [<a href="/pubmed/21553119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21553119</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.deng.2006.1416">Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. <span><span class="ref-journal">Nucleic Acids Research. </span>2006;<span class="ref-vol">34</span>:1416–26.</span> [<a href="/pmc/articles/PMC1390683/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1390683</span></a>] [<a href="/pubmed/16522651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16522651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.deng.2002.171">Deng CX. Tumor formation in Brca1 conditional mutant mice. <span><span class="ref-journal">Environ Mol Mutagen. </span>2002;<span class="ref-vol">39</span>:171–7.</span> [<a href="/pubmed/11921186" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11921186</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.diez.2010.221">Diez O, Guti&#x000e9;rrez-Enr&#x000ed;quez S, Mediano C, Masas M, Saura C, Gadea N, Balma&#x000f1;a J. A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">121</span>:221–5.</span> [<a href="/pubmed/19649703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19649703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ding.2011.771">Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2011;<span class="ref-vol">126</span>:771–8.</span> [<a href="/pmc/articles/PMC3059396/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3059396</span></a>] [<a href="/pubmed/20927582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20927582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.domchek.2011">Domchek SM, Friebel T, Neuhausen SL, Lynch HT, Singer CF, Eeles RA, Isaacs C, Tung NM, Ganz PA, Couch FJ, Weitzel JN, Olopade OI, Rubinstein WS, Tomlinson GE, Pichert GC, Daly MB, Matloff ET, Evans DG, Garber JE, Rebbeck TR, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer. Abstract 1501. Chicago, IL: ASCO Annual Meeting; 2011.</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.easton.1995.265">Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. <span><span class="ref-journal">Am J Hum Genet. </span>1995;<span class="ref-vol">56</span>:265–71.</span> [<a href="/pmc/articles/PMC1801337/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1801337</span></a>] [<a href="/pubmed/7825587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7825587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.eggington.2012">Eggington JM, Burbidge LA, Roa BB, Pruss D, Bowles K, Rosenthal E, Wenstrup R. Current variant of uncertain significance rates in BRCA1/2 and Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EPCAM). Poster. Charlotte, NC: American College of Medical Genetics Annual Clinical Genetics Meeting. 2012.</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.eisen.2008.1361">Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA, et al.  Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. <span><span class="ref-journal">J Natl Cancer Inst. </span>2008;<span class="ref-vol">100</span>:1361–7.</span> [<a href="/pmc/articles/PMC2556701/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2556701</span></a>] [<a href="/pubmed/18812548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18812548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.euhus.2002.844">Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. <span><span class="ref-journal">J Natl Cancer Inst. </span>2002;<span class="ref-vol">94</span>:844–51.</span> [<a href="/pubmed/12048272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12048272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.evans.2004.474">Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:474–80.</span> [<a href="/pmc/articles/PMC1735807/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735807</span></a>] [<a href="/pubmed/15173236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15173236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.evans.2011.520">Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:520–2.</span> [<a href="/pubmed/21653198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21653198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.evans.2010.710">Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. <span><span class="ref-journal">J Med Genet. </span>2010;<span class="ref-vol">47</span>:710–1.</span> [<a href="/pubmed/20587410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20587410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ewald.2009.437">Ewald IP, Ribeiro PL, Palmero EI, Cossio SL, Giugliani R, Ashton-Prolla P. Genomic rearrangements in BRCA1 and BRCA2: A literature review. <span><span class="ref-journal">Genet Mol Biol. </span>2009;<span class="ref-vol">32</span>:437–46.</span> [<a href="/pmc/articles/PMC3036053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3036053</span></a>] [<a href="/pubmed/21637503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21637503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ferla.2007.vi93">Ferla R, Cal&#x000f2; V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A. Founder mutations in BRCA1 and BRCA2 genes. <span><span class="ref-journal">Ann Oncol. </span>2007;<span class="ref-vol">18</span> Suppl 6:vi93–8.</span> [<a href="/pubmed/17591843" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17591843</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ferrone.2009.433">Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit Robson ME. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>:433–8.</span> [<a href="/pmc/articles/PMC3657622/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3657622</span></a>] [<a href="/pubmed/19064968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19064968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ford.1994.692">Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. <span><span class="ref-journal">Lancet. </span>1994;<span class="ref-vol">343</span>:692–5.</span> [<a href="/pubmed/7907678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7907678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ford.1998.676">Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:676–89.</span> [<a href="/pmc/articles/PMC1376944/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376944</span></a>] [<a href="/pubmed/9497246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9497246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.frank.2002.1480">Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. <span><span class="ref-journal">J Clin Oncol. </span>2002;<span class="ref-vol">20</span>:1480–90.</span> [<a href="/pubmed/11896095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11896095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.friebel.2014.dju091">Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. <span><span class="ref-journal">J Natl Cancer Inst. </span>2014;<span class="ref-vol">106</span>:dju091.</span> [<a href="/pmc/articles/PMC4081625/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4081625</span></a>] [<a href="/pubmed/24824314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24824314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.fujiwara.2012.1170">Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria, identification of a BRCA1 ovarian cancer phenotype. <span><span class="ref-journal">Am J Surg Pathol. </span>2012;<span class="ref-vol">36</span>:1170–7.</span> [<a href="/pmc/articles/PMC3422129/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3422129</span></a>] [<a href="/pubmed/22790858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22790858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.gallagher.2010.2115">Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:2115–21.</span> [<a href="/pmc/articles/PMC3713614/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3713614</span></a>] [<a href="/pubmed/20215531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20215531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.garciacasado.2011.134">Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, Garcia A, Llombart P, Lopez-Guerrero JA. A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. <span><span class="ref-journal">BMC Med Genet. </span>2011;<span class="ref-vol">12</span>:134.</span> [<a href="/pmc/articles/PMC3207938/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3207938</span></a>] [<a href="/pubmed/21989022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21989022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.goldgar.2011.r73">Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM. BCFR; kConFab, Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G. Rare variants in the ATM gene and risk of breast cancer. <span><span class="ref-journal">Breast Cancer Res. </span>2011;<span class="ref-vol">13</span>:R73.</span> [<a href="/pmc/articles/PMC3236337/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3236337</span></a>] [<a href="/pubmed/21787400" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21787400</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.goshen.2000.477">Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, Fyles A, Mitchell M, Narod SA. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? <span><span class="ref-journal">Gynecol Oncol. </span>2000;<span class="ref-vol">79</span>:477–81.</span> [<a href="/pubmed/11104623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11104623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.gowen.1998.1009">Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. <span><span class="ref-journal">Science. </span>1998;<span class="ref-vol">281</span>:1009–12.</span> [<a href="/pubmed/9703501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9703501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.graeser.2009.5887">Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>:5887–92.</span> [<a href="/pubmed/19858402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19858402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.gruber.2002.1344">Gruber SB, Petersen GM. Cancer risks in BRCA1 carriers: time for the next generation of studies. <span><span class="ref-journal">J Natl Cancer Inst. </span>2002;<span class="ref-vol">94</span>:1344–5.</span> [<a href="/pubmed/12237273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12237273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.gudas.1996.717">Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ 3rd, Cowan KH. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. <span><span class="ref-journal">Cell Growth Differ. </span>1996;<span class="ref-vol">7</span>:717–23.</span> [<a href="/pubmed/8780885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8780885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.haffty.2002.1471">Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">359</span>:1471–7.</span> [<a href="/pubmed/11988246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11988246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.hakem.1996.1009">Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. <span><span class="ref-journal">Cell. </span>1996;<span class="ref-vol">85</span>:1009–23.</span> [<a href="/pubmed/8674108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8674108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.hansen.2008.58">Hansen TV, Bisgaard ML, J&#x000f8;nson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H, Ejlertsen B, Nielsen FC. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. <span><span class="ref-journal">BMC Med Genet. </span>2008;<span class="ref-vol">9</span>:58.</span> [<a href="/pmc/articles/PMC2478678/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2478678</span></a>] [<a href="/pubmed/18597679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18597679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.hearle.2003.458">Hearle N, Damato BE, Humphreys J, Wixey J, Green H, Stone J, Easton DF, Houlston RS. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2003;<span class="ref-vol">44</span>:458–62.</span> [<a href="/pubmed/12556369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12556369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.hobert.2009.687">Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:687–94.</span> [<a href="/pubmed/19668082" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19668082</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.holt.1996.298">Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">12</span>:298–302.</span> [<a href="/pubmed/8589721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8589721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.howlett.2002.606">Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. <span><span class="ref-journal">Science. </span>2002;<span class="ref-vol">297</span>:606–9.</span> [<a href="/pubmed/12065746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12065746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.iqbal.2012.2005">Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachaqui M, Ping S, Narod SA, et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. <span><span class="ref-journal">Br J Cancer. </span>2012;<span class="ref-vol">107</span>:2005–9.</span> [<a href="/pmc/articles/PMC3516682/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3516682</span></a>] [<a href="/pubmed/23099806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23099806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.jernstr_m.2004.1094">Jernstr&#x000f6;m H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <span><span class="ref-journal">J Natl Cancer Inst. </span>2004;<span class="ref-vol">96</span>:1094–8.</span> [<a href="/pubmed/15265971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15265971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.jones.2009.217">Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. <span><span class="ref-journal">Science. </span>2009;<span class="ref-vol">324</span>:217.</span> [<a href="/pmc/articles/PMC2684332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2684332</span></a>] [<a href="/pubmed/19264984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19264984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.judkins.2012.5210">Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup RJ, Roa BB. Clinical significance of large rearrangements in BRCA1 and BRCA2. <span><span class="ref-journal">Cancer. </span>2012;<span class="ref-vol">118</span>:5210–6.</span> [<a href="/pmc/articles/PMC3532625/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3532625</span></a>] [<a href="/pubmed/22544547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22544547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kang.2010.579">Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, Thong MK, Mohd Taib NA, Yip CH, Teo SH. Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">124</span>:579–84.</span> [<a href="/pubmed/20617377" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20617377</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kauff.2002.1609">Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:1609–15.</span> [<a href="/pubmed/12023992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12023992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kaurah.2007.2360">Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. <span><span class="ref-journal">JAMA. </span>2007;<span class="ref-vol">297</span>:2360–72.</span> [<a href="/pubmed/17545690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17545690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ketabi.2011.462">Ketabi Z, Bartuma K, Bernstein I, Malander S, Gronberg H, Bjorck E, Holck S, Nilbert M. Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors. <span><span class="ref-journal">Gynecol Oncol. </span>2011;<span class="ref-vol">121</span>:462–5.</span> [<a href="/pubmed/21388660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21388660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.king.2003.643">King MC, Marks JH, Mandell JB, et al.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. <span><span class="ref-journal">Science. </span>2003;<span class="ref-vol">302</span>:643–6.</span> [<a href="/pubmed/14576434" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14576434</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.king.2001.2251">King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B., National Surgical Adjuvant Breast and Bowel Project.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. <span><span class="ref-journal">JAMA. </span>2001;<span class="ref-vol">286</span>:2251–6.</span> [<a href="/pubmed/11710890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11710890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kirova.2005.2304">Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A, et al.  Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. <span><span class="ref-journal">Eur J Cancer. </span>2005;<span class="ref-vol">41</span>:2304–11.</span> [<a href="/pubmed/16140006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16140006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kotejarai.2011.1230">Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D, Collaborators UKGPCS, Goldgar D, Eeles R. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. <span><span class="ref-journal">Br J Cancer. </span>2011;<span class="ref-vol">105</span>:1230–4.</span> [<a href="/pmc/articles/PMC3208504/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3208504</span></a>] [<a href="/pubmed/21952622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21952622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kotsopoulos.2016.365">Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2016;<span class="ref-vol">155</span>:365–73.</span> [<a href="/pubmed/26780555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26780555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.kwong.2011.233">Kwong A, Ng EK, Tang EY, Wong CL, Law FB, Leung CP, Chan A, Cheung MT, To MY, Ma ES, West DW, Ford JM. A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. <span><span class="ref-journal">Fam Cancer. </span>2011;<span class="ref-vol">10</span>:233–7.</span> [<a href="/pmc/articles/PMC3100488/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3100488</span></a>] [<a href="/pubmed/21404118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21404118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.lauper.2013.e59709">Lauper JM, Krause A, Vaughan TL, Monnat RJ Jr. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e59709.</span> [<a href="/pmc/articles/PMC3613408/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3613408</span></a>] [<a href="/pubmed/23573208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23573208</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.lee.2011.4373">Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span>:4373–80.</span> [<a href="/pmc/articles/PMC3221522/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3221522</span></a>] [<a href="/pubmed/22010008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22010008</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.leongamornlert.2012.1697">Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D, Collaborators UKGPCS, Goldgar D, Eeles R, Kote-Jarai Z. Germline BRCA1 mutations increase prostate cancer risk. <span><span class="ref-journal">Br J Cancer. </span>2012;<span class="ref-vol">106</span>:1697–701.</span> [<a href="/pmc/articles/PMC3349179/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3349179</span></a>] [<a href="/pubmed/22516946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22516946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.lubinski.2004.1">Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, Sun P, Narod SA. Cancer variation associated with the position of the mutation in the BRCA2 gene. <span><span class="ref-journal">Fam Cancer. </span>2004;<span class="ref-vol">3</span>:1–10.</span> [<a href="/pubmed/15131399" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15131399</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ludwig.1997.1226">Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. <span><span class="ref-journal">Genes Dev. </span>1997;<span class="ref-vol">11</span>:1226–41.</span> [<a href="/pubmed/9171368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9171368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.malone.2010.2404">Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch C, Boice JD, Anton-Culver H, Bernstein JL. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. <span><span class="ref-journal">J Clin Oncol. </span>2010;<span class="ref-vol">28</span>:2404–10.</span> [<a href="/pmc/articles/PMC2881721/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2881721</span></a>] [<a href="/pubmed/20368571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20368571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.marshall.2009.427">Marshall M, Solomon S, Lawrence Wickerham D. Case report: de novo BRCA2 gene mutation in a 35-year-old woman with breast cancer. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">76</span>:427–30.</span> [<a href="/pubmed/19796187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19796187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.mavaddat.2013.812">Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. <span><span class="ref-journal">J Natl Cancer Inst. </span>2013;<span class="ref-vol">105</span>:812–22.</span> [<a href="/pubmed/23628597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23628597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.mclaughlin.2013.141">McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. <span><span class="ref-journal">J Natl Cancer Inst. </span>2013;<span class="ref-vol">105</span>:141–8.</span> [<a href="/pmc/articles/PMC3611851/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3611851</span></a>] [<a href="/pubmed/23257159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23257159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.meeks.2015.djv315">Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A, James PA, Bruinsma F, Campbell IG, Broeks A, Schmidt MK, Hogervorst FB, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Gu&#x000e9;nel P, Truong T, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, Gonz&#x000e1;lez-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, Lu KH, Liang D, Hildebrant MA, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Br&#x000fc;ning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM, Aittom&#x000e4;ki K, Butzow R, Bogdanova NV, D&#x000f6;rk T, Lindblom A, Margolin S, Rantala J, Kosma VM, Mannermaa A, Lambrechts D, Neven P, Claes KB, Maerken TV, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Goode EL, Hart SN, Shimelis H, Cunningham JM, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale AL, Kristensen V, Salvesen HB, Bjorge L, Bandera EV, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylk&#x000e4;s K, Tollenaar RA, Ouweland AM, Andrulis IL, Knight JA, Narod S, Devilee P, Winqvist R, Figueroa J, Greene MH, Mai PL, Loud JT, Garc&#x000ed;a-Closas M, Schoemaker MJ, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park SK, Teo SH, Yoon SY, Matsuo K, Hosono S, Woo YL, Gao YT, Foretova L, Singer CF, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov EN, Hulick PJ, Olopade OI, Senter L, Olah E, Doherty JA, Schildkraut J, Koppert LB, Kiemeney LA, Massuger LF, Cook LS, Pejovic T, Li J, Borg A, &#x000d6;fverholm A, Rossing MA, Wentzensen N, Henriksson K, Cox A, Cross SS, Pasini BJ, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson BA, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, Antoniou AC, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning AM, Pharoah PD, Hall P, Easton DF, Couch FJ, Spurdle AB, Goldgar DE, et al.  BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. <span><span class="ref-journal">J Natl Cancer Inst. </span>2015;<span class="ref-vol">108</span>:djv315.</span> [<a href="/pmc/articles/PMC4907358/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4907358</span></a>] [<a href="/pubmed/26586665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26586665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.metcalfe.2011a.1384">Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <span><span class="ref-journal">Br J Cancer. </span>2011a;<span class="ref-vol">104</span>:1384–92.</span> [<a href="/pmc/articles/PMC3101934/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3101934</span></a>] [<a href="/pubmed/21487411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21487411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.metcalfe.2011b.287">Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2011b;<span class="ref-vol">127</span>:287–96.</span> [<a href="/pubmed/21221768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21221768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.metcalfe.2005.222">Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. <span><span class="ref-journal">Gynecol Oncol. </span>2005;<span class="ref-vol">96</span>:222–6.</span> [<a href="/pubmed/15589605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15589605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.meyer.2012.e38361">Meyer P, Landgraf K, H&#x000f6;gel B, Eiermann W, Ataseven B. BRCA2 mutations and triple-negative breast cancer. <span><span class="ref-journal">PLoS One. </span>2012;<span class="ref-vol">7</span>:e38361.</span> [<a href="/pmc/articles/PMC3364210/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3364210</span></a>] [<a href="/pubmed/22666503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22666503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.miki.1994.66">Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Brostow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnik MH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <span><span class="ref-journal">Science. </span>1994;<span class="ref-vol">266</span>:66–71.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.mocci.2013.803">Mocci E, Milne RL, M&#x000e9;ndez-Villamil EY, Hopper JL, John EM, Andrulis IL, Chung WK, Daly M, Buys SS, Nalats N, Goldgar DE. Risk of pancreatic cacner in breast cancer families form the breast cancer family registry. <span><span class="ref-journal">Cancer Epidemiol Biomarkers Prev. </span>2013;<span class="ref-vol">22</span>:803–11.</span> [<a href="/pmc/articles/PMC3739843/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3739843</span></a>] [<a href="/pubmed/23456555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23456555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.moran.2012.235">Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. <span><span class="ref-journal">Fam Cancer. </span>2012;<span class="ref-vol">11</span>:235–42.</span> [<a href="/pubmed/22187320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22187320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.morimatsu.1998.3441">Morimatsu M, Donoho G, Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. <span><span class="ref-journal">Cancer Res. </span>1998;<span class="ref-vol">58</span>:3441–7.</span> [<a href="/pubmed/9699678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9699678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.m_ller.2002.1014">M&#x000fc;ller A, Edmonston TB, Corao DA, Rose DG, Palazzo JP, Becker H, Fry RD, Rueschoff J, Fishel R. Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. <span><span class="ref-journal">Cancer Res. </span>2002;<span class="ref-vol">62</span>:1014–9.</span> [<a href="/pubmed/11861375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11861375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.narod.2000.1876">Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. <span><span class="ref-journal">Lancet. </span>2000;<span class="ref-vol">356</span>:1876–81.</span> [<a href="/pubmed/11130383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11130383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.n_slundkoch.2016.1208">N&#x000e4;slund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. <span><span class="ref-journal">J Clin Oncol. </span>2016;<span class="ref-vol">34</span>:1208–16.</span> [<a href="/pubmed/26884562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26884562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ngeow.2014.1818">Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. <span><span class="ref-journal">J Clin Oncol. </span>2014;<span class="ref-vol">32</span>:1818–24.</span> [<a href="/pmc/articles/PMC4039869/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4039869</span></a>] [<a href="/pubmed/24778394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24778394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.niell.2004.15">Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. <span><span class="ref-journal">J Natl Cancer Inst. </span>2004;<span class="ref-vol">96</span>:15–21.</span> [<a href="/pubmed/14709734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14709734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.nieuwenhuis.2014.57">Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Yntema HG, Evans DG, Colas C, M&#x000f8;ller P, Hes FJ, Hodgson SV, Olderode-Berends MJ, Aretz S, Heinimann K, G&#x000f3;mez Garc&#x000ed;a EB, Douglas F, Spigelman A, Timshel S, Lindor NM, Vasen HF. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. <span><span class="ref-journal">Fam Cancer. </span>2014;<span class="ref-vol">13</span>:57–63.</span> [<a href="/pubmed/23934601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23934601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ouchi.1998.2302">Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53- dependent gene expression. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1998;<span class="ref-vol">95</span>:2302–6.</span> [<a href="/pmc/articles/PMC19327/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC19327</span></a>] [<a href="/pubmed/9482880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9482880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.palma.2008.7006">Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. <span><span class="ref-journal">Cancer Res. </span>2008;<span class="ref-vol">68</span>:7006–14.</span> [<a href="/pmc/articles/PMC2752710/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2752710</span></a>] [<a href="/pubmed/18703817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18703817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.parmigiani.1998.145">Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:145–58.</span> [<a href="/pmc/articles/PMC1376797/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376797</span></a>] [<a href="/pubmed/9443863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9443863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.pierce.2010.389">Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmana J, Meirovitz A, Domchek SM. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">121</span>:389–98.</span> [<a href="/pmc/articles/PMC2936479/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2936479</span></a>] [<a href="/pubmed/20411323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20411323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rajan.1996.13078">Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1996;<span class="ref-vol">93</span>:13078–83.</span> [<a href="/pmc/articles/PMC24049/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC24049</span></a>] [<a href="/pubmed/8917547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8917547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rakha.2008.2568">Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:2568–81.</span> [<a href="/pubmed/18487574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18487574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rebbeck.2005.7804">Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL, et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. <span><span class="ref-journal">J Clin Oncol. </span>2005;<span class="ref-vol">23</span>:7804–10.</span> [<a href="/pubmed/16219936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16219936</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rebbeck.2002.1616">Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:1616–22.</span> [<a href="/pubmed/12023993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12023993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rebbeck.2015.1347">Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen TV, Ram&#x000f3;n y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittom&#x000e4;ki K, van der Hout AH, Hogervorst FB, Verhoef S, Coll&#x000e9;e JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, G&#x000f3;mez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Z&#x00142;owocka-Per&#x00142;owska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I, et al.  Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <span><span class="ref-journal">JAMA. </span>2015;<span class="ref-vol">313</span>:1347–61.</span> [<a href="/pmc/articles/PMC4537700/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4537700</span></a>] [<a href="/pubmed/25849179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25849179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.renwick.2006.873">Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N, et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:873–5.</span> [<a href="/pubmed/16832357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16832357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.risch.2006.1694">Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. <span><span class="ref-journal">J Natl Cancer Inst. </span>2006;<span class="ref-vol">98</span>:1694–706.</span> [<a href="/pubmed/17148771" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17148771</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.roberts.2012.41">Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP. ATM mutations in patients with hereditary pancreatic cancer. <span><span class="ref-journal">Cancer Discov. </span>2012;<span class="ref-vol">2</span>:41–6.</span> [<a href="/pmc/articles/PMC3676748/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3676748</span></a>] [<a href="/pubmed/22585167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22585167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.robson.1998.1642">Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K. BRCA-associated breast cancer in young women. <span><span class="ref-journal">J Clin Oncol. </span>1998;<span class="ref-vol">16</span>:1642–9.</span> [<a href="/pubmed/9586873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9586873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.robson.2005.44">Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. <span><span class="ref-journal">Cancer. </span>2005;<span class="ref-vol">103</span>:44–51.</span> [<a href="/pubmed/15558796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15558796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.robson.2004.r8">Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, B&#x000e9;gin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. <span><span class="ref-journal">Breast Cancer Res. </span>2004;<span class="ref-vol">6</span>:R8–R17.</span> [<a href="/pmc/articles/PMC314444/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC314444</span></a>] [<a href="/pubmed/14680495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14680495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rosen.2006.175">Rosen EM, Fan S, Ma X. BRCA1 regulation of transcription. <span><span class="ref-journal">Cancer Lett. </span>2006;<span class="ref-vol">236</span>:175–85.</span> [<a href="/pubmed/15975711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15975711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.ruijs.2010.421">Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van't Veer LJ. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. <span><span class="ref-journal">J Med Genet. </span>2010;<span class="ref-vol">47</span>:421–8.</span> [<a href="/pubmed/20522432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20522432</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.rutter.2003.1072">Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. <span><span class="ref-journal">J Natl Cancer Inst. </span>2003;<span class="ref-vol">95</span>:1072–8.</span> [<a href="/pubmed/12865453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12865453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.sankaran.2006.4100">Sankaran S, Starita LM, Simons AM, Parvin JD. Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function. <span><span class="ref-journal">Cancer Res. </span>2006;<span class="ref-vol">66</span>:4100–7.</span> [<a href="/pubmed/16618730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16618730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.satagopan.2002.3776">Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Ovarian cancer risk in Ashkenazi Jewish carrier of BRCA1 and BRCA2 mutations. <span><span class="ref-journal">Clin Cancer Res. </span>2002;<span class="ref-vol">8</span>:3776–81.</span> [<a href="/pubmed/12473589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12473589</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.satagopan.2001.467">Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. <span><span class="ref-journal">Cancer Epidemiol Biomarkers Prev. </span>2001;<span class="ref-vol">10</span>:467–73.</span> [<a href="/pubmed/11352856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11352856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.seynaeve.2004.1150">Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. <span><span class="ref-journal">Eur J Cancer. </span>2004;<span class="ref-vol">40</span>:1150–8.</span> [<a href="/pubmed/15110878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15110878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.sharan.1997.804">Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. <span><span class="ref-journal">Nature. </span>1997;<span class="ref-vol">386</span>:804–10.</span> [<a href="/pubmed/9126738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9126738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.slater.2010.490">Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, Bartsch DK. PALB2 mutations in European familial pancreatic cancer families. <span><span class="ref-journal">Clin Genet. </span>2010;<span class="ref-vol">78</span>:490–4.</span> [<a href="/pubmed/20412113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20412113</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.smith.1992.128">Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. <span><span class="ref-journal">Nat Genet. </span>1992;<span class="ref-vol">2</span>:128–31.</span> [<a href="/pubmed/1303261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1303261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.somasundaram.1997.187">Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. <span><span class="ref-journal">Nature. </span>1997;<span class="ref-vol">389</span>:187–90.</span> [<a href="/pubmed/9296497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9296497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.spurdle.2012.525">Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C, Van Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM, Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A, Caputo S, Sinilnikova OM, Lidereau R, Couch FJ, Guidugli L, Hansen TV, Thomassen M, Eccles DM, Tucker K, Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg &#x000c5;, Vreeswijk MP, Goldgar DE, et al.  BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. <span><span class="ref-journal">J Med Genet. </span>2012;<span class="ref-vol">49</span>:525–32.</span> [<a href="/pmc/articles/PMC3810416/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3810416</span></a>] [<a href="/pubmed/22889855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22889855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.stecklein.2012.178">Stecklein SR, Jensen RA. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. <span><span class="ref-journal">Transl Res. </span>2012;<span class="ref-vol">160</span>:178–97.</span> [<a href="/pubmed/22683426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22683426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.suzuki.1997.1242">Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW. Brca2 is required for embryonic cellular proliferation in the mouse. <span><span class="ref-journal">Genes Dev. </span>1997;<span class="ref-vol">11</span>:1242–52.</span> [<a href="/pubmed/9171369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9171369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.tai.2007.1811">Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. <span><span class="ref-journal">J Natl Cancer Inst. </span>2007;<span class="ref-vol">99</span>:1811–4.</span> [<a href="/pmc/articles/PMC2267289/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2267289</span></a>] [<a href="/pubmed/18042939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18042939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.tan.2012.400">Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. <span><span class="ref-journal">Clin Cancer Res. </span>2012;<span class="ref-vol">18</span>:400–7.</span> [<a href="/pmc/articles/PMC3261579/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3261579</span></a>] [<a href="/pubmed/22252256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22252256</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.tavtigian.2009.427">Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vall&#x000e9;e MP, Voegele C, Webb PM, Whiteman DC, Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G, et al.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">85</span>:427–46.</span> [<a href="/pmc/articles/PMC2756555/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2756555</span></a>] [<a href="/pubmed/19781682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19781682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.templeton.2016.e0154789">Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, &#x00160;eruga B, Srikanthan A, Pandiella A, Amir E, Ocana A. Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: a systematic review and meta-regression. <span><span class="ref-journal">PLoS One. </span>2016;<span class="ref-vol">11</span>:e0154789.</span> [<a href="/pmc/articles/PMC4858163/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4858163</span></a>] [<a href="/pubmed/27149669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27149669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.thompson.2001.410">Thompson D, Easton D, et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:410–9.</span> [<a href="/pmc/articles/PMC1235274/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235274</span></a>] [<a href="/pubmed/11170890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11170890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.thompson.2002.1358">Thompson D, Easton DF. The breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. <span><span class="ref-journal">J Natl Cancer Inst. </span>2002;<span class="ref-vol">94</span>:1358–65.</span> [<a href="/pubmed/12237281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12237281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.thorne.2011.1002">Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL, Bolton D, et al.  Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. <span><span class="ref-journal">Cancer Prev Res (Phila). </span>2011;<span class="ref-vol">4</span>:1002–10.</span> [<a href="/pubmed/21733824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21733824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.tyrer.2004.1111">Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. <span><span class="ref-journal">Stat Med. </span>2004;<span class="ref-vol">23</span>:1111–30.</span> [<a href="/pubmed/15057881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15057881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.van_asperen.2005.711">van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE, et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:711–9.</span> [<a href="/pmc/articles/PMC1736136/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1736136</span></a>] [<a href="/pubmed/16141007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16141007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.van_den_broek.2015.e0120189">van den Broek AJ, Schmidt MK, van 't Veer LJ, Tollenaar RA, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0120189.</span> [<a href="/pmc/articles/PMC4376645/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4376645</span></a>] [<a href="/pubmed/25816289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25816289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.van_der_kolk.2010.643">van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits JE, de Vries J, van der Hout AH, Oosterwijk JC. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">124</span>:643–51.</span> [<a href="/pubmed/20204502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20204502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.vaughn.1996.4590">Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. Cell cycle control of BRCA2. <span><span class="ref-journal">Cancer Res. </span>1996;<span class="ref-vol">56</span>:4590–4.</span> [<a href="/pubmed/8840967" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8840967</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.venkitaraman.2001.3591">Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. <span><span class="ref-journal">J Cell Sci. </span>2001;<span class="ref-vol">114</span>:3591–8.</span> [<a href="/pubmed/11707511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11707511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.venkitaraman.2002.171">Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. <span><span class="ref-journal">Cell. </span>2002;<span class="ref-vol">108</span>:171–82.</span> [<a href="/pubmed/11832208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11832208</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.verhoog.2000.119s">Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. <span><span class="ref-journal">J Clin Oncol. </span>2000;<span class="ref-vol">18</span>:119S–24S.</span> [<a href="/pubmed/11060339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11060339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.vichapat.2012.3478">Vichapat V, Garmo H, Holmqusit M, Liljegren G, Warnberg F, Llambe M, Fornander T, Adolfsson J, Luchtenborg M, Holmberg L. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. <span><span class="ref-journal">J Clin Oncol. </span>2012;<span class="ref-vol">30</span>:3478–85.</span> [<a href="/pubmed/22927521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22927521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.walsh.2010.2214">Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le Marchand L, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:2214–24.</span> [<a href="/pmc/articles/PMC2848890/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2848890</span></a>] [<a href="/pubmed/20215533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20215533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.weischer.2007.57">Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:57–63.</span> [<a href="/pubmed/16880452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16880452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.whittemore.2004a.1911">Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, Daly M, Usinowicz MB, Garlinghouse-Jones K, Ponder BA, Buys S, Senie R, Andrulis I, John E, Hopper JL, Piver MS. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. <span><span class="ref-journal">Br J Cancer. </span>2004a;<span class="ref-vol">91</span>:1911–5.</span> [<a href="/pmc/articles/PMC2410144/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2410144</span></a>] [<a href="/pubmed/15545966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15545966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.whittemore.2004b.2078">Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, Dicioccio R, Felberg A, West DW. Prevalence of BRCA1 mutation carriers among U.S.non-Hispanic Whites. <span><span class="ref-journal">Cancer Epidemiol Biomarkers Prev. </span>2004b;<span class="ref-vol">13</span>:2078–83.</span> [<a href="/pubmed/15598764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15598764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.wong.1997.31941">Wong AKC, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. <span><span class="ref-journal">J Biol Chem. </span>1997;<span class="ref-vol">272</span>:31941–4.</span> [<a href="/pubmed/9405383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9405383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.yates.2011.463">Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. <span><span class="ref-journal">Cancer Prev Res (Phila). </span>2011;<span class="ref-vol">4</span>:463–70.</span> [<a href="/pmc/articles/PMC3048908/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3048908</span></a>] [<a href="/pubmed/21278312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21278312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.zhang.1998.433">Zhang H, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: collision or collusion? <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">92</span>:433–6.</span> [<a href="/pubmed/9491884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9491884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.zhang.2011.97">Zhang L, Fleischut MH, Kohut K, Spencer S, Wong K, Stadler ZK, Kauff ND, Offit K, Robson ME. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">80</span>:97–8.</span> [<a href="/pubmed/21649643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21649643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.zhong.2015.211">Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. <span><span class="ref-journal">Clin Cancer Res. </span>2015;<span class="ref-vol">21</span>:211–20.</span> [<a href="/pmc/articles/PMC4286460/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4286460</span></a>] [<a href="/pubmed/25348513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25348513</span></a>]</div></li></ul></div><div id="brca1.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.boughey.2010.3591">Boughey JC, Hartmann LC, Anderson SS, Degnim AC, Vierkant RA, Reynolds CA, Frost MH, Pankratz VS. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. <span><span class="ref-journal">J Clin Oncol. </span>2010;<span class="ref-vol">28</span>:3591–6.</span> [<a href="/pmc/articles/PMC2917314/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2917314</span></a>] [<a href="/pubmed/20606088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20606088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.garber.2005.276">Garber JE, Offit K. Hereditary cancer predisposition syndromes. <span><span class="ref-journal">J Clin Oncol. </span>2005;<span class="ref-vol">23</span>:276–92.</span> [<a href="/pubmed/15637391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15637391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF.narod.2005.1656">Narod SA, Offit K. Prevention and management of hereditary breast cancer. <span><span class="ref-journal">J Clin Oncol. </span>2005;<span class="ref-vol">23</span>:1656–63.</span> [<a href="/pubmed/15755973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15755973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="brca1.REF171">National Cancer Institute. Genetics of breast and gynecologic cancers (PDQ<sup>&#x000ae;</sup>). Bethesda, MD: National Cancer Institute. Available <a href="http://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 3-20-18.</div></li></ul></div></div><div id="brca1.Chapter_Notes"><h2 id="_brca1_Chapter_Notes_">Chapter Notes</h2><div id="brca1.Author_History"><h3>Author History</h3><p>Julie O Bars Culver, MS; Fred Hutchinson Cancer Research Center (1998-2011) <br />Wylie Burke, MD, PhD; University of Washington (1998-2005) <br />Mary B Daly, MD, PhD (1998-present) <br />Gerald L Feldman, MD, PhD; Wayne State University School of Medicine (2002-2016) <br />Judith L Hull, MS; Memorial Sloan-Kettering Cancer Center (1998-2005) <br />Ephrat Levy-Lahad, MD; Sharre Zedek Medical Center (1998-2007) <br />Tuya Pal, MD (2016-present)<br />Nancie Petrucelli, MS (2002-present)</p></div><div id="brca1.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 December 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 September 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 January 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 June 2007 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>5 December 2005 (cd) Revision: Differential Diagnosis</div></li><li class="half_rhythm"><div>3 September 2004 (jbc) Revision: Genetically Related Disorders</div></li><li class="half_rhythm"><div>29 March 2004 (ca) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>4 March 2000 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>4 September 1998 (pb) Review posted to live Web site</div></li><li class="half_rhythm"><div>January 1998 (jbc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1247</span><span class="label">PMID: <a href="/pubmed/20301425" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301425</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bcl11a-id/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/spg17/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1247&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1247/?report=reader">PubReader</a></li><li><a href="/books/NBK1247/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1247" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1247" style="display:none" title="Cite this Page"><div class="bk_tt">Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1247/pdf/Bookshelf_NBK1247.pdf">PDF version of this page</a> (660K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#brca1.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#brca1.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#brca1.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#brca1.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#brca1.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#brca1.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#brca1.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#brca1.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#brca1.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#brca1.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#brca1.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3161[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HMMR</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=207[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AKT1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=83990[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRIP1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9821[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RB1CC1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4835[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NQO2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8493[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PPM1D</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5245[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PHB</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7157[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TP53</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3845[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRAS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8438[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RAD54L</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=672[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRCA1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=580[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BARD1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=675[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRCA2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=79728[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PALB2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=999[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CDH1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5888[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RAD51</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5002[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC22A18</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5290[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PIK3CA</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=472[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ATM</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7517[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">XRCC3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=11200[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CHEK2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=841[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CASP8</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2099[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ESR1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1247+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1478032" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1478032" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1478032" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1478032" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10388011" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.</a><span class="source">[Oncologist. 1996]</span><div class="brieflinkpop offscreen_noflow">Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Piver MS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Oncologist. 1996; 1(5):326-330. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301488" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schneider K, Zelley K, Nichols KE, Garber J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15516851" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.</a><span class="source">[Fam Cancer. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Casey MJ, Bewtra C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Fam Cancer. 2004; 3(3-4):265-81. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30872561" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.</a><span class="source">[Ann Ital Chir. 2019]</span><div class="brieflinkpop offscreen_noflow">Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Ital Chir. 2019; 90:1-2. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15863145" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.</a><span class="source">[Gynecol Oncol. 2005]</span><div class="brieflinkpop offscreen_noflow">Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gynecol Oncol. 2005 May; 97(2):457-67. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301425" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301425" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc9276dd21425a25a4fe9b">BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer - GeneReviews®</a><div class="ralinkpop offscreen_noflow">BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:20:54-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C7C39DFC874F10000000005760283&amp;ncbi_session=CE8C7C39DFC92751_1398SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1247%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1247&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1247/&amp;ncbi_pagename=BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C7C39DFC92751_1398SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>